

1 **Inside the Genome: Understanding Genetic Influences on Oxidative Stress**

2 Hari Krishnan Krishnamurthy^{1*}, Imbaasree Rajavelu², Michelle Pereira², Vasanth
3 Jayaraman¹, Karthik Krishna¹, Tianhao Wang¹, Kang Bei¹, John J. Rajasekaran¹

4 1 Vibrant Sciences LLC., San Carlos, CA, United States of America,

5 2 Vibrant America LLC., San Carlos, CA, United States of America

6 **Acknowledgments**

7 We acknowledge Vibrant America LLC for supporting this research.

8 **Disclosure**

9 The data and materials in this manuscript have not been published elsewhere and are not under
10 consideration by another journal.

11 **Funding**

12 Vibrant America provided funding for this study in the form of salaries for authors [Hari
13 Krishnan Krishnamurthy, Imbaasree Rajavelu, Michelle Pereira, Vasanth Jayaraman, Karthik
14 Krishna, Tianhao Wang, Kang Bei, and John J. Rajasekaran]. The specific roles of these
15 authors are articulated in the ‘author contributions’ section. The funders had no role in study
16 design, data collection, and analysis, decision to publish, or preparation of the manuscript.

17 **Conflicts of Interest**

18 The authors have read the journal’s policy and the authors of this manuscript have the following
19 competing interests: Rajavelu and Pereira are paid employees of Vibrant America LLC.
20 Jayaraman, Krishna, Wang, Bei, Rajasekaran, and Krishnamurthy are paid employees of
21 Vibrant Sciences LLC. Vibrant Sciences or Vibrant America is a commercial lab that performs
22 genetic testing for oxidative stress related gene polymorphisms. Vibrant Sciences or Vibrant
23 America could benefit from increased testing based on the results. There are no patents,
24 products in development, or marketed products to declare.

25 .

26 **Author Contributions**

27 Conception: Hari Krishnan Krishnamurthy, John J. Rajasekaran, and Vasanth Jayaraman.
28 Manuscript preparation: Hari Krishnan Krishnamurthy, Imbaasree Rajavelu, Michelle Pereira,
29 Vasanth Jayaraman, Karthik Krishna, Tianhao Wang, Kang Bei, and John J. Rajasekaran. All
30 the authors read and approved the final manuscript.

31 **Data Availability**

32 The data used to support the findings of this study are available from the corresponding
33 author upon request.

34 **Consent for publication**

35 Not applicable

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63 **Abstract**

64 Genetics is a key factor that governs the susceptibility to oxidative stress. In the body, oxidative
65 burden is regulated by the balance between the prooxidant genes that orchestrate processes that
66 produce oxidant species, while the antioxidant genes aid those involved in scavenging these
67 species. Repair genes help in detecting and repairing the damage caused by oxidant species.
68 Together, the three components aid in maintaining the oxidative balance in the body. Genetic
69 variations can influence the expression and activity of the encoded proteins which can then
70 affect their efficiency in regulating redox processes, thereby increasing the risk of oxidative
71 stress. This review studies single nucleotide polymorphisms (SNPs) that bear relevance to
72 oxidative stress by exploring the variations in the prooxidant genes, such as XDH, CYBA,
73 CYP1A1, PTGS2, NOS, and MAO and antioxidant genes including SOD, CAT, GPX, GSS,
74 GLUL, GSR, GSTM1, GSTM5, GSTP1, TXN and HMOX1. The review also assesses the
75 complexities of DNA repair genes including OGG1, NEIL1, NEIL2, MUTYH, APEX1,
76 PARP1, XRCC1, XPD, XRCC3, and the protein repair gene, MSRA. Early identification of
77 individuals at the increased risk of oxidative stress is possible from the assessment of these
78 genes. Integrating genetic insights into oxidative stress management measures can pave the
79 way for personalized medicine that tailors' healthcare approaches to individual genetic profiles.
80 Effective genetic assessment along with routine quantification of biological markers can
81 improve and monitor treatment strategies, enhancing mitigation approaches that maintain
82 cellular health and promote longevity.

83 Keywords: oxidative stress, reactive oxygen species, genetic polymorphisms, superoxides

84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99

100 Introduction

101 Oxygen is a fundamental element for life and plays a crucial role in extracting energy through
102 oxidation processes in the human body. This metabolic necessity, while essential, concurrently
103 gives rise to transient entities, including reactive oxygen species (ROS) and reactive nitrogen
104 species (RNS), primarily originating from the mitochondria [1]. Although pivotal for immune
105 defense and cellular signaling, an excess of ROS and RNS can harm the body by modifying
106 lipids, DNA, RNA, and proteins, instigating detrimental oxidative reactions [2]. To counteract
107 oxidative damage, the human body has evolved a sophisticated antioxidant defense mechanism
108 comprising endogenous and exogenous antioxidants. Antioxidants play a crucial role in
109 protecting against oxidative stress by preventing the formation of reactive species, scavenging,
110 neutralizing, and removing reactive species, inhibiting oxidative chain reactions, and chelating
111 reactive metals, therefore combatting oxidative stress. [3]. Oxidative stress (OS) is defined as
112 “an imbalance between oxidants and antioxidants in favor of the oxidants, leading to a
113 disruption of redox signaling and molecular damage” [4]. Infections and inflammatory
114 processes can endogenously contribute to the generation of oxidant species. In addition,
115 exogenous sources such as toxins, ultraviolet (UV) radiation, cigarette smoking, alcohol
116 consumption, and ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) can also result
117 in the increased generation of oxidant species [5].

118 The delicate equilibrium between oxidants and antioxidants has garnered attention due to its
119 association with the onset and/or progression of several diseases, including cancer, diabetes,
120 metabolic disorders, atherosclerosis, and cardiovascular diseases (CVD) [6]. Elevated levels of
121 ROS and RNS attack cellular macromolecules which can trigger fundamental changes at the
122 cellular level, leading to chronic inflammation, DNA damage, and disruptions in cell signaling
123 pathways. Alterations in these critical pathways can be associated with the pathogenesis of
124 various diseases [2]. For instance, in cardiovascular diseases like atherosclerosis, oxidative
125 stress can contribute to the development of arterial plaques [8]. In diabetes, oxidative stress is
126 implicated in insulin resistance and pancreatic beta-cell dysfunction [8]. Persistent oxidative
127 stress can also contribute to the development and promotion of cancer by causing genetic
128 mutations, promoting angiogenesis, and facilitating metastasis [7]. The global prevalence of
129 these disorders underscores the significance of screening for oxidative stress.

130 Oxidative stress is known to be influenced by intrinsic elements such as genetic predispositions
131 and epigenetic modifications [9]. Prooxidant genes such as XDH, CYBA, CYP1A1, and
132 PTGS2 encoding the enzymes, xanthine oxidase, NADPH oxidase, CYP1A1 enzyme, and
133 cyclooxygenase-2, respectively, are involved in the generation of reactive species. The various
134 forms of nitric oxide synthase encoded by NOS1, NOS2, and NOS3, while monoamine
135 oxidases encoded by the MAO genes also produce oxidant species. Variations in these genes
136 might pose the risk of higher oxidant production. Antioxidant genes, such as SOD, CAT, and
137 GPX encode to the primary antioxidant enzymes, superoxide dismutase, catalase, and
138 glutathione peroxidase, respectively. Enzymes involved in the glutathione system including
139 glutathione synthetase (GSS gene), glutamate-cysteine ligase (GLUL), glutathione reductase
140 (GSR), and glutathione transferases (GSTM1, GSTM5, GSTP1) play critical roles in
141 maintaining the glutathione antioxidant pool. Additionally, the enzymes, thioredoxins (TXN)
142 and heme oxygenase – 1 (HMOX1) contribute to the body’s antioxidant system by maintaining
143 redox homeostasis. Polymorphisms in these antioxidant genes can affect their activity and
144 efficiency, thereby affecting the body’s antioxidant defences. For instance, variations in the

145 SOD gene influence the enzyme's function and reduce its activity, increasing the susceptibility
146 to oxidative stress [10].

147 Lipids are highly susceptible to oxidative damage, leading to lipid peroxidation and the
148 formation of reactive aldehydes and lipid hydroperoxides. To counteract lipid peroxidation, the
149 body employs repair mechanisms involving antioxidant enzymes and lipid repair proteins.
150 However, research on genes involved in lipid repair is currently limited [11]. In contrast, the
151 body has developed robust repair mechanisms against oxidative DNA damage, crucial for
152 maintaining genomic integrity and preventing mutagenesis. Key genes involved in various
153 DNA repair pathways, such as OGG1, NEIL1, NEIL2, MUTYH, APEX1, PARP1, XRCC1,
154 XPD, and XRCC3 play essential roles in repairing oxidative DNA lesions. Polymorphisms in
155 these genes can disrupt the efficiency or fidelity of DNA repair mechanisms, leading to the
156 accumulation of oxidative DNA damage and impairing the cell's ability to cope with oxidative
157 stress [12]. Similarly, repair mechanisms safeguard protein integrity, involving molecular
158 chaperones and proteolytic systems. The MSRA gene, responsible for regulating protein
159 oxidation, plays a crucial role in the reversible oxidation-reduction of methionine sulfoxide in
160 proteins to methionine. Polymorphisms in the MSRA gene can impair this process, affecting
161 protein function and integrity [13].

162 Understanding the genetics of prooxidants, antioxidants, and oxidative repair mechanism genes
163 can provide insights into the genetic factors influencing oxidative stress-related disease risk.
164 Genetic assessment for these genes might enable the early identification of individuals at higher
165 risk of oxidative stress. Moreover, the exploration into the genetic landscape opens a promising
166 avenue for personalized medicine, where interventions can be tailored based on an individual's
167 unique genetic profile.

168 **Overview of Oxidative stress**

169 **Oxidants, Free Radical Production, and Antioxidants**

170 The generation of oxidant species involves both enzymatic and nonenzymatic reactions [14].
171 Enzymatic reactions in the respiratory chain, prostaglandin synthesis, phagocytosis, and the
172 cytochrome P450 system significantly contribute to ROS production. Key enzymes, including
173 NADPH oxidase, and xanthine oxidase play crucial roles in synthesizing superoxide radicals
174 ($O_2^{\cdot-}$), leading to the formation of hydrogen peroxide (H_2O_2), hydroxyl radicals ($\cdot OH$),
175 peroxynitrite ($ONOO^-$), and hypochlorous acid ($HOCl$). H_2O_2 is a nonradical compound,
176 generated by various oxidase enzymes, such as amino acid oxidase and xanthine oxidase. The
177 highly reactive hydroxyl radical ($\cdot OH$) is formed through the interaction of $O_2^{\cdot-}$ with H_2O_2 ,
178 catalysed by Fe^{2+} or Cu^+ in the Fenton reaction. Additionally, the nitric oxide radical ($NO\cdot$) is
179 enzymatically synthesized from the oxidation of arginine to citrulline by nitric oxide synthase
180 (NOS) [14] (Figure 1). Nonenzymatic reactions also contribute to free radical production,
181 especially during mitochondrial respiration, where oxygen reacts with organic compounds.
182 Exposure to toxins and ionizing radiation trigger nonenzymatic free radical formation [14].

183 Free radicals originate from both endogenous and exogenous sources [15]. Endogenous
184 production is linked to immune cell activation, inflammation, ischemia, infection, cancer,
185 excessive exercise, mental stress, and aging. Exogenous sources include exposure to toxins
186 such as environmental pollutants, heavy metals (Cd, Hg, Pb, Fe, and as), certain drugs
187 (cyclosporine, tacrolimus, gentamycin, and bleomycin), chemical solvents, cigarette smoke,

188 alcohol consumption, and radiation exposure [15-16]. In the case of exogenous substances,
189 these substances upon entering the body, undergo degradation or metabolism, resulting in the
190 generation of free radicals as by-products. At low or moderate concentrations, ROS and RNS
191 act as weapons for the host defence system. Phagocytes release $O_2^{\cdot-}$ during immune responses
192 to destroy invading pathogens, underscoring the dual nature of reactive species [16]. Nitric
193 oxide ($^{\cdot}NO$) is an important vasodilator and a cellular redox regulator [16].

194 To counteract oxidative stress, the body employs mechanisms involving antioxidants, either
195 endogenously generated or externally supplied through foods. Antioxidants neutralize excess
196 free radicals, protecting cells and contributing to disease prevention [17]. Endogenous
197 antioxidants are classified as enzymatic antioxidants and non-enzymatic antioxidants. The
198 primary antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and
199 glutathione peroxidase (GPx) directly neutralize ROS and RNS. SOD catalyzes the dismutation
200 of $O_2^{\cdot-}$ into H_2O_2 , which is then transformed into water (H_2O) and oxygen (O_2) by CAT or GPx.
201 Glutathione is an integral antioxidant in the body and it orchestrates its antioxidant functions
202 with the help of various enzymes that together form the 'glutathione system.' Glutamate-
203 cysteine ligase (GLUL) catalyzes the formation of the precursor to GSH while glutathione
204 synthetase (GSS) is one of the enzymes participating GSH synthesis. GPx removes H_2O_2 by
205 using it to oxidize reduced glutathione (GSH) into oxidized glutathione (GSSG) [17] (Figure
206 1).

207 Glutathione reductase (GR) regenerates GSH from GSSG utilizing NADPH as a source of
208 reducing power [18]. The glutathione enzyme family, glutathione S-transferases (GSTs) also
209 contribute to glutathione-mediated antioxidant actions. Additionally, the thioredoxin system
210 comprising thioredoxin (Trx) and thioredoxin reductase (TR) mediate antioxidant functions by
211 using NADPH. Heme oxygenase (HO) is another important enzyme that regulates oxidative
212 stress by maintaining heme homeostasis (Figure 1). In addition to these internal enzymatic
213 antioxidant defences, the body also has non-enzymatic antioxidants that are further divided into
214 endogenous non-enzymatic antioxidants (e.g., glutathione, alpha- lipoic acid, coenzyme Q10,
215 melatonin, uric acid, bilirubin,) and exogenous non-enzymatic antioxidants (e.g., vitamin A, E,
216 C, selenium, zinc, carotenoids, trace metals, flavonoids, omega-3 and omega-6 fatty acids)
217 [18].

218 The enzymatic and non-enzymatic antioxidants together mount effective antioxidant defences
219 against oxidant species in the body. The antioxidant process operates through chain-breaking
220 or prevention mechanisms. In chain-breaking, antioxidants stabilize free radicals formed
221 during reactions, preventing further damage, while in prevention, antioxidant enzymes reduce
222 the rate of chain initiation, scavenging initiating free radicals or stabilizing transition metal
223 radicals [19]. This intricate process is critical for maintaining redox homeostasis and preventing
224 oxidative damage [19].

225 **Prooxidant genes in oxidative stress**

226 **Xanthine Oxidase**

227 Xanthine oxidase (XO) is a molybdoflavoprotein hydroxylase that can act both as an oxidase
228 (XO) and reductase (called xanthine dehydrogenase). It is encoded by the XDH gene. Both
229 forms of the enzyme aid in the final stage of purine catabolism. They catalyze the last two
230 oxidative reactions that convert hypoxanthine to xanthine and xanthine to uric acid, a well-

231 known antioxidant. However, this process results in the generation of $O_2^{\cdot-}$ and H_2O_2 [20]
232 (Figure 2). Additionally, XO is involved in the hydroxylation of various substrates and the
233 production of NO^{\cdot} under hypoxic conditions from nitrates and nitrites [21]. This increases the
234 availability NO^{\cdot} to react with $O_2^{\cdot-}$ to give $ONOO^-$ radicals [21]. This dual functionality of XO,
235 in participating in the synthesis of uric acid and also in being a source of ROS, underscores its
236 significance in oxidative stress pathways.

237 Polymorphisms in the prooxidant, XDH gene associated with its increased activity results in
238 higher ROS and RNS production leading to oxidative stress. Increased production of ROS by
239 XDH has been described in experimental models of salt-sensitive, and glucocorticoid-induced
240 hypertension [22]. Some studies have suggested that XDH activity is enhanced in patients with
241 hypertension and a higher production of H_2O_2 mediated by XDH in hypertensives as compared
242 with controls has been described [23]. Among several XDH polymorphisms, variants at
243 positions 565+64CT and -337GA are of particular interest. Individuals carrying specific
244 genotypes, such as the CC genotype of the 565+64CT polymorphism, have been found to
245 exhibit higher levels of oxidative stress markers, including malondialdehyde (MDA) and 8-
246 oxo-deoxyguanosine (8-oxo-dG) as compared to individuals with the CT and TT genotypes.
247 This suggests that C allele enhances oxidase function and may predispose individuals to
248 increased oxidative stress, potentially contributing to a range of oxidative stress-related
249 conditions [24]. Similarly, the -337GA polymorphism has shown associations with oxidative
250 stress markers, primarily through elevated MDA levels seen among individuals with AA and
251 AG genotypes in comparison with the GG genotypes. These studies strengthen the potential
252 role of XDH variants in the risk of oxidative stress and related diseases such as hypertension
253 [25].

254 **NADPH oxidase**

255 NADPH oxidase (NOX) is a transmembrane enzyme located in intracellular organelles. The
256 CYBA gene that encodes the p22phox subunit of NOX. NOX is a transmembrane enzyme and
257 is involved in the production of reactive species. It is present in intracellular organelles and
258 comprises several isoforms, including NOX1–5, NOX oxidase 1 and 2, NOX organizer 1, and
259 NOX activator 1. All of these, under normal conditions produce modest levels of $O_2^{\cdot-}$,
260 contributing to fundamental cellular processes. However, exposure to diverse stimuli can
261 amplify ROS production, triggering intracellular signalling pathways and consequently,
262 oxidative stress. The p22phox subunit, originating from the CYBA gene, plays a vital role in
263 NOX function by stabilizing the catalytic subunit and providing a docking site for cytosolic
264 factors, thereby facilitating NADPH oxidase activity [26].

265 Upon translocation to the membrane and co-localization with p22phox and other NADPH
266 subunits (p67phox, p47phox, and p40phox), NADPH oxidase stands out as the sole known
267 enzyme family dedicated to producing ROS as its primary function. NOX orchestrates the
268 transfer of electrons from cytosolic NADPH, traversing through FAD to penetrate the
269 membrane via hemes, reaching oxygen and resulting in $O_2^{\cdot-}$ generation in the cytoplasm.
270 Therefore, the CYBA gene through NADPH oxidase is involved in maintaining cellular
271 processes by the generation of ROS [27] (Figure 2).

272 Numerous genetic polymorphisms have been reported within the promoter and exonic regions
273 of the CYBA gene. Some of these polymorphisms influence gene expression and subsequently,
274 NADPH oxidase activity, leading to elevated free radical formation. Among several CYBA

275 polymorphisms, rs4673 (C242T), rs9932581 (A-930G), and rs8854 variants have been
276 extensively studied [28]. In the promoter region, G alleles of rs9932581 and T alleles of rs8854
277 are associated with increased promoter activity, resulting in elevated oxidative stress [29].
278 These polymorphisms are in the potential binding site of C/EBP (CCAAT/enhancer-binding
279 protein) transcription factors, suggesting their role in modulating CYBA promoter activity and
280 influencing CYBA transcription [30]. Studies have linked these genetic variations to
281 susceptibility to oxidative stress-related diseases like hypertension, accompanied with
282 increased oxidative stress markers such as 8-isoprostaglandin F₂α (8-isoPGF₂α) levels, along
283 with reduced antioxidant CAT activity [29].

284

285 For the rs4673 polymorphism, different rates of O₂^{•-} production have been demonstrated
286 depending on the genotype. The T allele is associated with reduced NADPH oxidase activity,
287 both at basal levels and when stimulated. This allele has been suggested to confer protection
288 against oxidative stress pathologies [31]. Studies in patients with obstructive sleep apnea
289 indicate that the CC genotype associates with higher oxidative marker levels, such as 8-
290 Isoprostane levels, while the TT genotype associates with lower 8-isoPGF₂α levels. This
291 suggests that individuals with the CC genotype exhibit higher CYBA activity and experience
292 increased oxidative stress compared to those with TT genotypes [32]. These genetic variations
293 exert a significant influence on oxidative stress markers, antioxidant activity, and disease
294 susceptibility.

295 **Cytochrome P450 family 1 subfamily A member 1**

296 Cytochrome P450 (CYP) enzymes, specifically the CYP1A subfamily constitute a diverse
297 group that plays pivotal roles in metabolizing both, internally generated (endobiotic) and
298 foreign (xenobiotic) substances within the human body [33]. CYP1A1 belongs to this
299 subfamily and it is mainly in extrahepatic tissues where it participates in the metabolism of a
300 vast number of endobiotics and xenobiotic such as toxins and drugs. However, CYP1A1's
301 metabolic activity also results in the generation of ROS as byproducts, particularly when
302 metabolizing certain procarcinogens like polycyclic aromatic hydrocarbons (PAHs) found in
303 environmental pollutants and food contaminants. The overexpression of CYP1A1 usually
304 caused due to exposure to PAHs results in the increase in ROS generation (Figure 2). As a
305 result, variations in this gene might have implications in oxidative stress [34].

306 The CYP1A1 gene exhibits the polymorphism, rs4646903, located in the 3'-UTR. In
307 rs4646903, the T>C alteration influences the enzyme's activity which results in the increase in
308 CYP1A1 activity [35]. As a result, individuals with variant genotypes (CC and TC) may
309 experience higher ROS production during metabolic reactions as opposed to those with the
310 wild-type genotype (TT) having optimum CYP1A1 activity [35]. It is fair to infer that the
311 rs4646903 polymorphism predisposes the CC and TC genotypes to increased oxidative stress.
312 This inference was supported by the observed increase in the levels of the oxidative marker,
313 MDA and the decrease in the antioxidant, GPx [36]. The SNP can predispose these individuals
314 to diseases associated with oxidative damage, such as chronic obstructive pulmonary disease
315 (COPD) and coronary artery disease [37].

316 **Cyclooxygenase-2**

317 The PTGS2 gene which is responsible for encoding the cyclooxygenase-2 (COX-2) enzyme,
318 plays a crucial role in susceptibility to oxidative stress. The enzyme contributes to the

319 production of inflammatory molecules by catalysing the conversion of arachidonic acid into
320 prostaglandins, specifically, prostaglandin G₂ and prostaglandin H₂. This process results in the
321 generation of O₂^{•-} and subsequently other oxidant species. Moreover, COX-2 expression is
322 upregulated during oxidative stress and inflammation. This creates a positive feedback loop
323 where COX-2 activity is further boosted increasing the production of pro-inflammatory
324 prostaglandins, which exacerbate oxidative stress and tissue damage [38,39]. Variations in the
325 COX-2 gene can be implicated in oxidative stress-related conditions such as cancer,
326 cardiovascular diseases, and neurodegenerative disorders.

327 Polymorphisms within the COX-2 gene, such as rs20417 (-765G > C) significantly influence
328 oxidative stress [40]. The rs20417 polymorphism situated upstream from the transcription start
329 site of the COX-2 gene introduces a critical alteration in a stimulatory protein binding site. This
330 genetic variation leads to a consequential increase in transcription activity, resulting in elevated
331 expression of the COX-2 enzyme [41]. The heightened expression of COX-2, in turn, is known
332 to play a significant role in the intricate relationship between oxidative stress and cancer
333 susceptibility [41]. By converting arachidonic acid into prostaglandins, COX-2 becomes a key
334 player in oxidative stress-mediated inflammation and cytokine production. The CC genotype
335 of rs20417 is associated with a higher incidence of oxidative stress [42,43]. This polymorphism
336 has been linked to a higher risk of colorectal and gastric diseases, potentially due to increase in
337 oxidative stress levels [44, 45].

338 **Nitric oxide synthase**

339 The family of nitric oxide synthase (NOS) proteins, which includes neuronal NOS (nNOS or
340 NOS 1), inducible NOS (iNOS or NOS 2), and endothelial NOS (eNOS or NOS 3), plays a
341 crucial role in catalyzing the oxidation of L-arginine, producing •NO and L-citrulline (Figure
342 3). These enzymes, encoded by separate genes, significantly contribute to cellular redox
343 balance and various cellular functions. Understanding the role of NOS proteins is essential,
344 especially considering that their genetic variations can impact •NO production.

345 •NO, a multifaceted molecule, acts as a chain-breaking antioxidant in free radical-mediated
346 lipid peroxidation. Optimal levels of •NO are important for vasodilation, host defence, and
347 other cellular signaling processes in the body. Generally, concentrations ranging from pico to
348 nanomolar levels are considered the optimum range for •NO, where it positively influences
349 various physiological processes. However, the oxidative status of the underlying tissue can
350 affect •NO synthesis and bioavailability. Elevated endogenous tissue oxidant levels can reduce
351 •NO levels aggravating NO-dependent oxidative stress. When tissue O₂^{•-} levels are higher, they
352 attack •NO to form the cytotoxic, ONOO⁻ (Figure 3). This indicates that low levels of •NO
353 contribute to oxidative stress. However, studies have proposed •NO to represent a 'double-
354 edged sword' with its overproduction leading to a multitude of •NO by-products implicated in
355 mutational events and carcinogenesis. It is hypothesized that metabolic oxygen and nitrogen
356 species from •NO may attack DNA bases, resulting in point mutations, strand breaks and
357 interactions with sulfhydryl groups potentially leading to carcinogenesis [46]. Therefore,
358 maintaining an optimum range of •NO levels is crucial. Exceedingly high or low •NO levels
359 can pose risks to cellular health, leading to oxidative stress-related conditions.

360 Exercise significantly impacts •NO production, especially concerning energy demand. •NO,
361 released by endothelial cells, plays a vital role in improving vascular function, leading to
362 reductions in blood pressure during physical activity. Chemical and physical stimuli regulate

363 NO production during exercise [47]. Individuals with high •NO expression levels, engaging in
364 short bouts of exercise can quickly increase NO biological activity, suggesting that less intense
365 exercise may be sufficient to maintain NO levels. Conversely, for those with low •NO
366 expression levels, prolonged training is beneficial as it leads to NO-dependent arterial
367 remodeling and normalization of shear stress response, potentially compensating for their
368 lower baseline NO levels. This understanding underscores the importance of tailoring exercise
369 interventions based on an individual's NO expression levels to optimize vascular health. [47-
370 48].

371 **Nitric oxide synthase - 1**

372 In the intron region of the NOS1 gene, the rs1879417 (g.117803515C > T) SNP has been
373 studied in the context with oxidative stress. The C allele at this intronic SNP may be associated
374 altered NOS1 function linked to an increased risk of oxidative stress-related conditions, such
375 as stroke, when compared to individuals with T alleles [49]. The diverse polymorphisms within
376 the NOS gene family, along with their associated genotypes underscore their significance in
377 modulating oxidative stress and their intricate involvement in various diseases.

378 **Nitric oxide synthase – 2**

379 In the NOS2 gene, three SNPs in the promoter region namely, -1659 C>T (rs8078340), -
380 1026G>T (rs2779249), and -277A>G (rs2779248) contribute to increase •NO production [47].
381 Specifically, the T alleles of rs8078340 and rs2779249, along with G alleles of rs2779248, lead
382 to higher •NO production. These "high •NO expressor" variants raise •NO levels, potentially
383 resulting in the generation of ROS and contributing to oxidative stress. Elevated concentrations
384 of •NO under certain circumstances can generate ONOO⁻ which is toxic and has carcinogenic
385 potential [47]. These polymorphisms are associated with conditions such as hypertension,
386 diabetes mellitus, stroke, hypercholesterolemia, atherosclerosis, cardiovascular diseases, and
387 kidney diseases.

388 **Nitric oxide synthase - 3**

389 Within the NOS3 gene, several notable polymorphisms, such as T-786C [50], G894T
390 (Glu298Asp) [51], and 27bp-VNTR [52] are linked to altered •NO production leading to
391 oxidative stress. For the SNPs, T-786C and G894T, the homozygous (NOS3-786 CC) and/or
392 heterozygous (NOS3 894 GT+TT) states are significantly associated with the with low •NO
393 and high oxidative stress [47]. Similarly, 27bp-VNTR is seen to result in low •NO
394 bioavailability leading to disease progression [47]. These polymorphisms, identified as low NO
395 expressor alleles/genotypes, result in a global reduction in •NO production due to a 50%
396 reduction in promoter activity. This reduction in •NO levels contribute to the observed
397 heightened oxidative stress in individuals carrying these risk alleles/genotypes.

398 **Monoamine oxidase - B**

399 Monoamine oxidases (MAOs) are mitochondrial enzymes that oxidize monoamines, producing
400 H₂O₂ and reactive aldehydes. There are two isoforms: MAO-A and MAO-B, with MAO-B
401 playing a key role in regulating intracellular redox balance. Disruptions in monoamine
402 metabolism and genetic variations in the MAO genes can cause oxidative stress, affecting
403 cellular redox balance [53, 54]. Among the MAO-B gene polymorphisms, rs1799836 is of great
404 importance. This polymorphism is in intron 13 of the MAO-B gene and is thought to disrupt

405 monoamine metabolism, leading to increased ROS production and oxidative stress within the
406 central nervous system [55]. In this polymorphism, the enzymatic activity of MAO-B is
407 affected; the A allele is associated with elevated MAO-B activity, while the G allele is linked
408 to lower MAO-B activity. Studies consistently show that individuals with the AA genotype
409 exhibit higher MAO-B enzyme activity and protein levels, confirming the involvement of the
410 A allele in heightened oxidative stress through increased MAO-B expression [55]. The
411 implications of rs1799836 extends to various neurodegenerative diseases such as Parkinson's
412 Disease (PD) and mental health conditions like bipolar disorder and panic disorder, mediated
413 by the A allele's effect in oxidative stress [56]. Table 1 provides a gist of the mechanisms by
414 which genetic polymorphisms influence prooxidant genes.

415 **Antioxidant genes in oxidative stress**

416 **Superoxide Dismutase**

417 Superoxide dismutase (SOD) is a group of enzymes found in oxygen-dependent organisms that
418 convert the highly reactive, $O_2^{\cdot-}$ into less reactive, H_2O_2 and oxygen (O_2) through redox
419 reactions of metal ions within their active sites [57] (Figure 2). This is the integral mechanism
420 by which SOD reduces oxidative stress in the body. Humans have three distinct SOD isoforms:
421 copper-zinc superoxide dismutase (Cu/ZnSOD) or SOD1, manganese superoxide dismutase
422 (MnSOD) or SOD2, and extracellular superoxide dismutase (ECSOD) or SOD3 [58]. Higher
423 levels of SOD can enhance the antioxidant defense system, reducing oxidative damage to cells
424 and potentially lowering the risk of various diseases, including cancer and neurodegenerative
425 disorders such as Alzheimer's disease [59-60].

426 **Superoxide Dismutase 1**

427 The SOD1 gene encodes for the enzyme, superoxide dismutase 1, present in cellular
428 compartments, including the cytosol, lysosomes, mitochondria, and endoplasmic reticulum.
429 Along with quenching $O_2^{\cdot-}$, SOD1 also functions as a transcription factor in the nucleus,
430 responding to oxidative stress by activating genes involved in ROS resistance [61].
431 Polymorphisms in the SOD1 gene have garnered attention due to their impact on oxidative
432 stress regulation. One extensively studied polymorphism is rs2234694 (+35A/C), situated at
433 the junction site between the intron and exon 3 [62]. The AA genotype is associated with an
434 increase in SOD1 enzyme activity, while the CC genotype correlates with a reduction in
435 enzymatic activity. This reduction in enzyme activity can lead to a compromised ability to
436 catalyze the conversion of $O_2^{\cdot-}$ into H_2O_2 and O_2 . As a result, the balance in the ROS levels is
437 disrupted, contributing to an increased susceptibility to oxidative stress [63]

438 Another notable polymorphism, rs36232792 is the 50 bp Insertion/Deletion (Ins/Del) located
439 1684 base pairs upstream of the ATG start codon in the SOD1 gene promoter region. The Del
440 allele in this polymorphism is linked to a reduction in promoter activity which can result in
441 decreased synthesis of the SOD1 enzyme, compromising its ability to neutralize $O_2^{\cdot-}$
442 radicals [64]. This reduction in enzymatic activity and compromised ROS detoxification might
443 contribute to an elevated oxidative stress environment within the cell [65]. The implications of
444 these SOD1 gene polymorphisms extend to various diseases such as heart failure, cancer,
445 diabetes, Down's syndrome, and amyotrophic lateral sclerosis owing to their roles in altered
446 redox signaling.

447 **Superoxide dismutase 2**

448 SOD2 encodes superoxide dismutase 2, that neutralizes $O_2^{\cdot-}$ generated during oxidative
449 phosphorylation [66]. As an antioxidant enzyme primarily localized in mitochondria, SOD2
450 plays a pivotal role in mitigating the harmful effects of $O_2^{\cdot-}$ byproducts produced during
451 cellular respiration [67-68]. The SOD2 polymorphism, rs4880 located in exon 2, introduces a
452 T to C substitution at position 2734, resulting in the SOD2 Ala16Val genotype. The Val allele,
453 a product of this SNP, significantly reduces SOD2 activity within the mitochondria via the
454 accelerated degradation of SOD2 Val mRNA. As a result, individuals with the Val variant may
455 experience higher oxidative stress. On the other hand, the Ala variants are associated with
456 higher SOD2 Ala mRNA synthesis in cells, thereby having optimum antioxidant function.
457 Additionally, the mitochondrial targeting sequence (MTS) of the SOD2 Ala precursor
458 facilitates efficient mitochondrial import through an α -helix conformation while the MTS of
459 the SOD2 Val precursor, adopting a β -sheet structure, results in a less efficient transport.
460 Consequently, SOD2 activity is approximately 40% higher following the mitochondrial import
461 in the SOD2 Ala precursor compared to its Val counterpart [69]. The SOD2 rs4880
462 polymorphism is believed to be associated with the susceptibility to various diseases, including
463 cancer, neurodegenerative disorders, chronic kidney disease (CKD), and cardiovascular
464 diseases [70].

465 **Superoxide Dismutase 3**

466 The SOD3 gene encodes for superoxide dismutase 3, playing a pivotal role as an extracellular
467 antioxidant enzyme. SOD3 is present in various body fluids, including plasma, lymph, and
468 synovial fluid where it neutralizes $O_2^{\cdot-}$ [71]. Particularly abundant in the lungs, it contributes
469 significantly to SOD activity in the airways and blood vessels protecting lung tissues from
470 oxidative stress.[72]. The SOD3 gene, particularly in exon 3, is linked to a commonly studied
471 SNP, specifically rs1799895 (R213G polymorphism). This SNP occurs in the heparin-binding
472 domain of the SOD3 gene, leading to an arginine-to-glycine amino acid substitution at position
473 213 (R213G). The genetic variations among CC genotypes resulting from this polymorphism
474 witness an impaired binding of ECSOD to the extracellular matrix, leading to lower tissue
475 levels of the enzyme in comparison to individuals carrying CG and GG genotypes [73]. This
476 reduction in ECSOD levels results in decreased protection of lung matrix components against
477 oxidative damage, indicating a potential involvement in the progression of chronic obstructive
478 pulmonary disease (COPD) and a decline in lung function over time [74-75].

479 **Catalase**

480 The CAT gene encodes the catalase enzyme, primarily found in cell peroxisomes and the
481 cytoplasm. It plays a crucial role in breaking down H_2O_2 produced during cellular respiration
482 into oxygen and water (Figure 2). Catalase is consistently active in systems involved in electron
483 transport with cytochromes, where H_2O_2 formation poses a threat to cellular integrity. Although
484 catalase is essential for eliminating excess H_2O_2 , its effectiveness decreases at low substrate
485 concentrations due to low affinity. In such cases, catalase requires additional hydrogen donors
486 like ethanol, formic, or ascorbic acids to effectively reduce H_2O_2 [76]. Genetic variations
487 within the CAT gene, particularly in its promoter region and coding sequence, can affect
488 catalase activity and may influence an individual's susceptibility to oxidative stress-related
489 diseases [77].

490 Variations in the CAT gene, including, -262C>T (rs1001179) [78], -844C/T or -844G/A
491 (rs769214) [79], and C111T (rs769217) [80] polymorphisms, are of significant interest due to

492 their implications in oxidative stress. These polymorphisms, located in the promoter region,
493 have been associated with alterations in catalase expression levels and activity. Specifically,
494 the rs1001179 polymorphism has been linked to variations in catalase levels and activity,
495 affecting the enzyme's ability to neutralize intracellular H₂O₂. Carriers of the TT-genotype of
496 the CAT gene rs1001179 polymorphism exhibited lower levels of catalase activity compared
497 to carriers of CT- and CC-genotypes, suggesting a potential role in oxidative stress [78]. The
498 other polymorphism, rs769214 has been associated with higher CAT activity in basal
499 conditions, depending on the binding site of the transcriptional factor PAX6. The T allele of
500 this polymorphism has been linked to increased CAT transcriptional activity [79, 81]. The
501 rs769217 is responsible for alterations in CAT activity, with individuals carrying the TT
502 genotype associated with lower CAT activity compared to those with the wild-type allele [80].
503 While the variant allele in rs769214 is improving the enzyme's activity, the variant allele of
504 rs769217 is reducing CAT activity reading to oxidative stress.

505 **Glutathione Peroxidase**

506 Glutathione Peroxidase (GPx) catalyzes the reduction of H₂O₂ to water and oxygen (Figure 2).
507 It also reduces peroxide radicals (ROO[•]) to alcohols and oxygen. Inactivity of GPx can result
508 in oxidative damage and trigger inflammatory pathways associated with nuclear factor-κB
509 (NF-κB) [82]. GPx comprises at least eight different members in humans, labeled GPx1 to
510 GPx8. These enzymes are found in various cellular compartments: GPx1 in the cytosol, GPx2
511 in the gastrointestinal system, GPx4 in membranes, and GPx3 in mitochondria/extracellular
512 space [83]. Most GPx enzymes use selenocysteine as a cofactor. While not all of them have
513 selenocysteine, they all rely on GSH in their active sites. GPx5, GPx7, and GPx8 lack
514 selenocysteine and instead use cysteine (CysGPxs). They are called thioredoxin-dependent
515 peroxidases and use cysteine (Cys) in their redox-active sites. This choice between cysteine
516 and selenocysteine offers a biological advantage by acting as an active site for redox actions
517 [84]. Due to their integral role in antioxidant activity, polymorphisms in GPx are implicated in
518 various conditions, including cancer, hypertension, vitiligo, neurodegenerative diseases, and
519 cardiovascular disease. [85].

520 **Glutathione Peroxidase 1**

521 Glutathione Peroxidase 1 (GPx1), also known as cellular GPx, is encoded by the GPX1 gene
522 and plays a crucial role in antioxidant defense mechanisms.[86]. Its significance is underscored
523 by its association with various health conditions, including coronary atherosclerosis in type 2
524 diabetic patients, as well as breast, lung, and bladder cancer. Furthermore, GPX1 has been
525 linked to vascular calcifications [87-88]. A notable polymorphism in the GPX1 gene,
526 rs1050450, is a leucine to proline change at codon position 198 (GPX1 Pro198Leu genotype).
527 This SNP involves a C>T substitution at position 198, resulting in the replacement of proline
528 (Pro) with leucine (Leu). The presence of the Leu allele in the GPX1 gene can affect the
529 protein's catalytic enzyme activity, substrate affinity, and structural stability. Specifically, the
530 GPX1 Leu variant exhibits lower enzymatic activity compared to the GPX1 Pro enzymes which
531 may weaken its ability to combat oxidative stress [89].

532 **Glutathione Peroxidase 3**

533 Glutathione Peroxidase 3 (GPx3) is primarily released into the extracellular space. It is encoded
534 by the GPX3 gene. GPx3 serves as a crucial antioxidant enzyme in the vasculature. Its main

535 function involves maintaining a delicate balance between various oxidant species and *NO, a
536 key vasorelaxant maintaining endothelial health. This equilibrium orchestrated by GPx3 is vital
537 for preserving the vascular bioavailability of NO, as other ROS can quickly react and deactivate
538 *NO [90]. Therefore, GPx3's role is essential in establishing an antithrombotic vascular
539 environment, averting endothelial dysfunction, and reducing the likelihood of diseases
540 associated with oxidative stress. Studies have identified the GPX3 gene to be associated with
541 the risk of arterial ischemic stroke, cerebral venous thrombosis, and sudden sensorineural
542 hearing loss (SSNHL), potentially due to its genetic influence on ROS [91]. For the rs3805435
543 in the GPX3 gene, individuals with the AA genotypes exhibited a deficiency in the GPx3
544 enzyme, leading to heightened extracellular oxidant stress, platelet activation, poor antioxidant
545 defenses, and potential oxidative modification of fibrinogen compared to the AG and GG
546 genotypes [92]. This sequence of events increases the risk of oxidative stress-related diseases,
547 including acute ischemic stroke, hypertension, platelet-dependent thrombosis, coronary artery
548 disease, and SSNHL [93].

549 **Glutathione Peroxidase 4**

550 Glutathione Peroxidase 4 (GPx4) encoded by the GPX4 gene, is a crucial enzyme essential for
551 cellular protection against oxidative stress. It plays a key role in reducing H₂O₂ and lipid
552 peroxides (LOOH) by utilizing GSH [94]. Variations in GPX4 gene is associated with the risk
553 of oxidative stress. The rs713041 SNP within the GPX4 gene introduces a C-T substitution,
554 specifically located in the 3' untranslated region (3'UTR) of the mRNA. This region plays a
555 crucial role in selenoprotein synthesis facilitating the incorporation of Secys. A genetic
556 variation in this region has the potential to influence GPx4 activity, particularly under
557 conditions of low selenium intake, rendering individuals more susceptible to oxidative stress-
558 related diseases [95]. The rs713041 polymorphism in GPX4 gene presents three distinct
559 genotypes, CC (Homozygous wild), CT (Heterozygous), TT (Homozygous mutant). In this
560 polymorphism, the C allele appears to confer a protective role against oxidative damage,
561 particularly when selenium levels are sufficient. It also contributes to maintaining GPx4
562 concentrations in lymphocytes, particularly for individuals with the CC genotype, compared to
563 those with the TT genotype in situations of inadequate selenium intake [95]. The substitution
564 of C allele with T allele has been linked to conditions such as obesity, endometriosis, thyroid
565 diseases, Alzheimer's disease, depression, multiple sclerosis, and various possibly owing to its
566 implication in oxidative stress [96].

567 **Glutathione system**

568 The glutathione system, anchored by glutathione (GSH), stands as a critical defense mechanism
569 against oxidative stress. GSH, a tripeptide composed of L-glutamate, L-cysteine, and glycine,
570 plays a pivotal role in maintaining cellular redox balance, essential for overall health [97]
571 (Figure 4). Its synthesis is orchestrated by two key enzymes, γ -Glutamyl cysteine synthase and
572 glutathione synthetase (GSS), fueled by ATP hydrolysis within the cytosol [98,101].
573 Additionally, glutamate-cysteine ligase (GLUL) catalyzes the formation of gamma-
574 glutamylcysteine, a precursor to GSH, in the initial stage of GSH synthesis. GSH functions as
575 a crucial substrate for enzymes like GPx, which scavenge peroxides to protect cells from
576 oxidative damage. Glutathione reductase (GR) aids in GSH regeneration by converting
577 oxidized glutathione (GSSG) back to its active form, thereby maintaining an optimal cellular
578 pool of GSH for antioxidant defense and redox homeostasis [99] (Figure 4). Furthermore,

579 glutathione S-transferases (GSTs), including GSTM, GSTP, and GSTA, among others,
580 contribute to detoxification processes within cells. These enzymes facilitate the conjugation of
581 GSH with electrophilic compounds, enhancing their solubility and facilitating their removal
582 from the cell. By neutralizing and eliminating harmful substances, GSTs play a crucial role in
583 protecting cells from oxidative damage and maintaining overall cellular health [100][102]
584 (Figure 4). Together, these elements form the robust, glutathione defense network crucial for
585 cellular health and resilience against oxidative insults. Polymorphisms in these enzymes have
586 been associated with various diseases.

587 **Glutathione synthetase**

588 The GSS gene encodes the glutathione synthetase enzyme (GSS), a critical player in the
589 synthesis of GSH [98]. GSS catalyzes the final step in GSH biosynthesis, using ATP to ligate
590 γ -glutamylcysteine with glycine. This is the final step in the synthesis of GSH [103]
591 Polymorphisms rs121909307 in the GSS gene can impact the activity of the GSS enzyme,
592 influencing the production of GSH and, consequently, the cellular response to oxidative stress.
593 Individuals with CC genotype exhibit optimum GSS activity, resulting in a lower risk of
594 oxidative stress. In contrast, those with CT or TT genotypes experience reduced GSS activity,
595 leading to decreased GSH production and a higher susceptibility to oxidative stress. The
596 polymorphic variations in the GSS gene directly correlate with the enzyme's function,
597 influencing the cellular antioxidant capacity and the ability to combat oxidative stress [104].
598 Individuals carrying the CT or TT genotypes may face an increased risk of conditions where
599 oxidative stress plays a pivotal role, such as neurodegenerative disorders, cardiovascular
600 diseases, or certain types of cancers [105].

601 **Glutamate ammonia ligase**

602 The GLUL gene encodes the enzyme glutamate ammonia ligase, also known as glutamine
603 synthetase. This enzyme is vital for maintaining cellular levels of glutamine, an amino acid
604 with various functions, including antioxidant properties [106]. Glutamine is a precursor for
605 GSH synthesis, crucial for controlling cellular redox status, highlighting the importance of the
606 GLUL gene. [106]. Polymorphisms in the GLUL gene, particularly, rs10911021 contribute to
607 variations in oxidative stress susceptibility. Homozygous wild individuals (TT) have sufficient
608 levels of glutamine synthetase and glutathione experience lower oxidative stress. Heterozygous
609 individuals (TC) with decreased levels of glutamine synthetase enzyme and glutathione may
610 face an increased risk of oxidative stress. Homozygous mutant individuals (CC) with reduced
611 levels of glutamine synthetase enzyme and glutathione exhibit heightened susceptibility to
612 oxidative stress [107].

613 **Glutathione reductase**

614 The GSR gene produces the glutathione-disulfide reductase protein, also known as the
615 glutathione reductase (GR) enzyme. This enzyme plays a crucial role in maintaining the
616 reduced form of GSH. This action mediated by GR is integral for replenishing the pool of GSH
617 [108]. Mutations in the GSR gene can cause hereditary glutathione reductase deficiency,
618 affecting cellular redox potential and increasing oxidative stress levels, especially in red blood
619 cells. This deficiency is linked to conditions such as hereditary hemolytic anemia. [108]. In the
620 polymorphism, rs8190955 in the GSR gene, individuals with the C allele have optimum levels
621 of GR while individuals with T allele are associated with a GR deficiency. As a result,

622 homozygous wild individuals with the CC genotype have appropriate antioxidant function and
623 lower levels of oxidative stress in red blood cells. On the other hand, heterozygous individuals
624 and homozygous mutant individuals with the CT and TT genotypes, respectively, have
625 impaired cellular redox potential and increased oxidative stress levels in red blood cells, owing
626 to the GR deficiency. This deficiency is associated with hereditary hemolytic anemia [108].

627 **Glutathione transferases**

628 Glutathione transferases (GST) form a critical enzyme family in cellular detoxification and
629 defense against oxidative stress. They facilitate the conjugation of GSH with electrophilic
630 compounds, aiding in the elimination of harmful substances. These enzymes are categorized
631 into cytosolic, mitochondrial, and microsomal members and are classified into multiple classes
632 including Alpha (A), Mu (M), and Pi (P), each with distinct subtypes. GSTs are expressed
633 predominantly in the liver and are involved in metabolizing various compounds. Their primary
634 function lies in rendering substances more water-soluble for excretion [109-110]. GSTs are
635 crucial for maintaining cellular homeostasis and preventing the accumulation of toxic
636 compounds, highlighting their role in cellular health maintenance. Genetic polymorphisms in
637 GST genes can alter enzyme activity and may exhibit altered detoxification capacities and
638 altered redox state, affecting susceptibility to diseases such as cancer, neurodegenerative
639 disorders, and cardiovascular diseases [111].

640 **Glutathione S-transferase Mu 1**

641 The GSTM1 gene produces an enzyme called glutathione S-transferase Mu 1 (GSMT1). The
642 enzyme is involved in detoxifying toxic compounds by catalyzing the conjugation of GSH with
643 a variety of electrophilic substrates, which makes the compounds more water-soluble and
644 facilitating their elimination from the body. Found in cellular compartments such as
645 mitochondria, lysosomes, and nuclei, this GSTM1 safeguards organelles, especially the
646 mitochondria from oxidative stress. It achieves this by preventing cardiolipin peroxidation and
647 cytochrome c release, making it a key regulator in fighting ROS [112]. Polymorphisms in the
648 GSTM1 gene contribute to variations in oxidative stress susceptibility. The rs366631
649 polymorphism is characterized by the T>C change. Individuals with the TT genotype exhibit
650 normal GSTM1 activity and have normal ROS scavenging abilities. On the other hand,
651 individuals with the CT and CC genotypes display reduced GSTM1 activity, making them
652 prone to oxidative stress due to the gene's diminished ability to scavenge oxidant species [113].

653 **Glutathione S-transferase 5**

654 Similarly, the GSTM5 gene is part of the GST family and encodes the enzyme, glutathione S-
655 transferase 5 (GSTM5) found in cellular compartments, such as the mitochondria. The enzyme
656 is crucial for protecting cell organelles from oxidative stress. For rs3754446 polymorphism in
657 GSTM5 individuals with TT genotypes exhibit normal GSTM5 activity, associated with
658 normal mitochondrial function and a lower risk of oxidative stress. In contrast, individuals with
659 GT and GG genotypes have altered GSTM5 activity and experience heightened oxidative stress
660 due to ROS accumulation in the mitochondria. [114]

661 **Glutathione S-transferase P1**

662 Glutathione S-transferase P1 (GSTP1) encoded by the GSTP1 gene, is a crucial enzyme found
663 throughout various cellular compartments such as the cytoplasm, mitochondria, lysosomes, and

664 nucleus. Its mitochondrial form plays a vital role in protecting organelles from oxidative stress
665 by inhibiting cardiolipin peroxidation and preventing cytochrome c release [109].
666 Polymorphisms within the GSTP1 gene, such as rs1138272 contribute to variations in oxidative
667 stress susceptibility. Individuals with the AA genotype exhibit normal gene activity, leading to
668 appropriate antioxidant activity and a lower risk of oxidative stress. In contrast, those with the
669 AG genotype show partially abnormal gene activity, resulting in decreased antioxidant activity
670 and an elevated risk of oxidative stress. Homozygous GG individuals experience decreased
671 gene activity, reduced antioxidant capacity, and a higher risk of oxidative stress. These
672 polymorphic variations directly impact the enzyme's activity, influencing the cellular response
673 to oxidative stress conditions [115].

674 **Thioredoxin system**

675 The thioredoxin system is crucial for regulating redox processes. It consists of thioredoxin
676 (Trx) and its partner, thioredoxin reductase (TR or TrxR), which uses NADPH to reduce Trx
677 [116] (Figure 5). Trx acts as an antioxidant by transferring electrons and protons, converting
678 disulfides into dithiols [116]. Trx maintains its active state mainly through the action of TR. It
679 can also be reactivated by glutaredoxin (Grx) within the glutathione system. Trx serves as an
680 antioxidant by directly quenching singlet oxygen (1O_2) and hydroxyl radicals ($\cdot OH$) or
681 indirectly by reducing oxidized proteins. A significant target of Trx is peroxiredoxin (Prx),
682 which directly reduces peroxides including H_2O_2 and various alkyl hydroperoxides. After Prx
683 reduces its target, Trx recycles the oxidized form of Prx back to its reduced state [117] (Figure
684 5). Overall, the thioredoxin system collaborates with the glutathione system to maintain the
685 organism's redox balance and protect against oxidative stress.

686 **Thioredoxin-2**

687 The TXN2 gene encodes thioredoxin-2, that reduces Prx dimers that are formed upon reaction
688 with H_2O_2 , thereby keeping Prx in their reduced and active state (Figure 5). TXN2 is essential
689 in particular for the efficient cycling of PRDX3, which indicates its importance in the body's
690 antioxidant defences [116]. Genetic variations within the TXN2 gene, particularly the
691 rs35045487 polymorphism is known to be crucial in modulating of oxidative stress. This
692 polymorphism, located in the proximal promoter region, involves an insertion/deletion
693 impacting the transcriptional activity [117]. Alleles A2 (GA insertion), A4 (G insertion), and
694 A5 (GGGA insertion) display decreased transcriptional activity, attributed to additional SP1
695 binding sites. This suggests a potential association with heightened oxidative stress, indicating
696 that individuals carrying these alleles may be predisposed to an imbalance in redox homeostasis
697 [118]. Similarly, the rs4485648 polymorphism in intron 1 of the TXN2 gene is known to
698 modulate oxidative stress-risk. The variant, 'TT' and 'CT' alleles of this polymorphism may
699 have altered TXN2 expression which may compromise its functionality leading to oxidative
700 stress. On the other hand, the 'CC' genotypes have appropriate gene expression associated with
701 optimum antioxidant function. A study showed that the TT and CT genotypes were associated
702 with the increased risk of diabetic retinopathy which could be mediated by elevated oxidative
703 stress [119-120].

704 **Heme oxygenase - 1**

705 Heme oxygenase (HO) plays a crucial role in regulating oxidative stress by maintaining heme
706 homeostasis. There are three isoforms of heme oxygenase: HO-1, HO-2, and HO-3. Among

707 these, HO-1 is upregulated in response to various stress stimuli, including oxidative stress. Its
708 activation is a protective response against oxidative stress, as it helps to degrade heme, a pro-
709 oxidant molecule, and generates products like biliverdin, which possess antioxidant properties
710 HO-1 expression is regulated by the transcription factor, Nrf2, which activates antioxidant
711 response elements (AREs) in the promoter region of the HMOX1 gene, encoding HO-1 [121-
712 122]. One notable polymorphism in the HMOX1 gene is rs2071746, where the A>T change is
713 linked to various oxidative stress-related diseases like sickle cell anemia, ischemic heart
714 disease, hypertension, and rheumatoid arthritis. Particularly in sickle cell anemia, the
715 rs2071746 TT genotype in the HMOX1 gene's promoter is associated with elevated fetal
716 hemoglobin (Hb F) levels. The T allele of rs2071746 is linked to reduced gene expression,
717 potentially leading to higher free heme concentration and stress-induced erythropoiesis,
718 consequently increasing Hb F levels. This association may contribute to the heightened
719 oxidative stress observed in sickle cell anemia. [123]. Table 2 summarizes the mechanisms by
720 which genetic polymorphisms influence antioxidant genes.

721 **Repair mechanisms in oxidative stress**

722 Biomolecules such as lipids, DNA, and proteins are prime targets of oxidative damage, leading
723 to significant cellular dysfunction and disease pathogenesis. Understanding the intricate
724 interplay between oxidative damage and the repair mechanisms that counteract the damage is
725 crucial for deciphering the molecular basis of diseases. This also aids in the development of
726 targeted interventions. Lipids, as integral components of cell membranes, are susceptible to
727 oxidative damage, resulting in lipid peroxidation and the generation of reactive aldehydes and
728 LOOH [124]. Repair mechanisms, including antioxidant enzymes and lipid repair proteins, act
729 to counteract lipid peroxidation damage [125]. In contrast, DNA, the fundamental repository
730 of genetic information, is continuously exposed to oxidative insults leading to various forms
731 of damage such as base alterations, single-strand breaks, and DNA-protein crosslinks. Robust
732 DNA repair mechanisms, including base excision repair (BER), nucleotide excision repair
733 (NER), and double-strand break repair (DSBR) play pivotal roles in maintaining genomic
734 integrity and mitigating the deleterious effects of oxidative DNA damage. Similarly, proteins
735 are also vulnerable to oxidative modifications like carbonylation, nitration, and disulfide bond
736 formation. Repair mechanisms, including molecular chaperones and proteolytic systems help
737 maintain protein integrity [126].

738 Despite significant strides in understanding the genes mediating repair mechanisms against
739 oxidative damage, a critical gap persists in our knowledge regarding the impact of genetic
740 polymorphisms on these processes. DNA repair mechanisms play critical roles in repairing
741 DNA, reducing the accumulation of DNA lesions, and maintaining the integrity of the genome.
742 Owing to this, considerable research has been dedicated to elucidating the role of genetic
743 variations in DNA repair pathways, while studies investigating polymorphisms in lipid and
744 protein repair mechanisms are relatively scarce [125]. In this review, we mainly focus on DNA
745 repair polymorphisms along with an additional polymorphism associated with protein repair.
746 Polymorphisms in various DNA repair genes can modulate individual DNA repair capacity,
747 thereby influencing genetic susceptibility to diseases. The limited information available for
748 lipid and protein repair pathways underscores the pressing need for further research in these
749 areas.

750 **DNA repair genes in oxidative stress**

751 **OGG1**

752 OGG1 is a vital DNA glycosylase in mammals. It plays a crucial role in the BER of oxidative
753 DNA damage, particularly the removal of 8-hydroxyguanine (8-OHG) and 2,6-diamino-4-
754 hydroxy-5-formamidopyrimidine (FapyG) lesions formed during oxidative stress. The human
755 OGG1 gene gives rise to multiple isoforms, with the primary variants, type 1a and 2a,
756 exhibiting distinct localizations in the nucleus and mitochondria, respectively [125].

757 The Ser326Cys polymorphism (rs1052133) in OGG1 is a well-studied genetic variation
758 associated with oxidative stress [126]. This SNP leads to a Ser-to-Cys substitution in the C-
759 terminal domain of OGG1, impacting its catalytic activity. Individuals with the Cys/Cys
760 genotype exhibit reduced BER repair rates of 8-OHG lesions, possibly due to lower enzymatic
761 activity associated with the Cys326 variant. The oxidation of Cys326, forming a disulfide bond
762 contributes to the diminished function of OGG1-Cys326. This polymorphism has been linked
763 to increased DNA damage, suggesting a higher susceptibility to oxidative stress [127]. A
764 significant association has been reported between the Ser326Cys polymorphism and lung
765 cancer risk, emphasizing OGG1's role in maintaining genomic stability [128]. Additionally,
766 OGG1 has implications in age-related diseases like Huntington's disease, where the Cys326
767 allele is linked to an earlier onset of the condition [129]. OGG1-Cys326 has also been identified
768 as a risk factor for bladder cancer and tumor recurrence in non-muscle invasive bladder cancer
769 patients [130]. Another OGG1 gene variant, Arg154His, with genotypes Arg/Arg, Arg/His,
770 and His/His, represents different combinations of alleles at the position 154 locus, potentially
771 influencing susceptibility to oxidative stress-related conditions. A gastric cancer cell line study
772 revealed that the His variant affects the recognition of cytosine paired with 8-OHG leading to
773 the inability to repair the DNA site, suggesting its potential involvement in disease progression
774 [131].

775 **NEIL1**

776 The NEIL1 gene belongs to the Nei-like protein family. It is a DNA glycosylase that plays a
777 crucial role in recognizing and excising oxidized bases from DNA, including 4,6-diamino-5-
778 formamidopyrimidine (FapyA) and FapyG. Unlike OGG1, NEIL1 does not specifically target
779 8-OHG. It exhibits a strong affinity for oxidized bases in single-stranded DNA as well as in
780 transcription and replication bubble DNA. NEIL1 operates in BER, utilizing a unique
781 elimination mechanism that establishes an apurinic/apyrimidinic endonuclease 1 enzyme
782 (APE1)-independent pathway, involving the APE1 enzyme responsible for repairing DNA
783 lesions within the BER pathway [132].

784 Relevant SNPs in the NEIL1 gene, such as Gly83Asp (rs5745906) and Cys136Arg
785 (rs5745907), impact the catalytic efficiency of the enzyme [132]. The Asp/Asp genotypes of
786 the rs5745906 SNP exhibit impaired function in excising certain DNA lesions in duplex DNA
787 while retaining the activity in single-stranded DNA. On the other hand, individuals with the
788 Arg/Arg genotype of the rs5745907 variation, have reduced DNA glycosylase activity for
789 oxidative base damage repair, altering protein folding and potentially affecting the enzyme's
790 capability to interact with nucleotides that have undergone a flipping motion or structural
791 change [132]. These genetic alterations in NEIL1 leading to inefficient DNA damage repair
792 can result in accumulation of oxidized DNA lesions. These lesions can interfere with DNA
793 replication and transcription, leading to mutations, and ultimately contributing to cellular
794 dysfunction and oxidative stress [133]. While no direct associations with specific diseases have

795 been established, the impact of NEIL1 polymorphisms on oxidative stress response
796 underscores their potential role in influencing overall health and disease susceptibility. Further
797 research is needed to elucidate the specific disease associations and clinical implications of
798 NEIL1 gene polymorphisms.

799 **NEIL2**

800 NEIL2 is another member of the DNA glycosylase family, and this gene consists of five exons.
801 NEIL2 functions as both, a DNA glycosylase integral to BER and an AP
802 (apurinic/aprimidinic) lyase, primarily targeting oxidative cytosine products with its highest
803 efficiency in 5-hydroxyuracil (5OHU) removal [132]. In terms of polymorphisms, relevant
804 SNPs in the NEIL2 gene include the following two in the 5' UTR region: ss74800505 (C > A)
805 and rs8191518 (C > G). These SNPs, when co-occurring, reduce NEIL2 expression levels and
806 affect DNA repair, potentially modifying disease susceptibility [131, 134]. The hypothesis
807 suggests that these polymorphisms may disrupt the binding of crucial transcriptional proteins.
808 Moreover, cultured lymphocytes carrying the heterozygous or homozygous ss74800505
809 variant show heightened mutagen sensitivity, implying that changes in NEIL2 expression
810 levels could affect DNA repair processes, potentially increasing induced mutagenesis [131].

811 **MUTYH**

812 MUTYH is a crucial DNA glycosylase integral to BER, playing a pivotal role in addressing
813 oxidative stress-induced DNA damage. Its primary function involves the elimination of
814 adenine bases paired with 8-OHG and 2-hydroxyadenine (2OHA) when erroneously paired
815 with guanine (G), leading to the formation of an AP site. The MUTYH gene, comprising
816 sixteen exons, generates various mature transcripts and gives rise to two distinct proteins with
817 distinct cellular localizations: mitochondrial (type 1 protein) and nuclear (type 2 protein). The
818 N-terminal domain of MUTYH interacts with the DNA strand containing the adenine substrate,
819 extruding adenine from the DNA helix. The C-terminal domain of MUTYH facilitates the
820 recognition of DNA strands containing 8-OHG and interacts with downstream BER proteins
821 [135].

822 Various human MUTYH variants, primarily arising from missense or insertion/deletion
823 mutations, exhibit significantly reduced DNA glycosylase activity. These mutations often
824 involve residue substitutions in the catalytic domain or the substrate recognition region,
825 highlighting their role in oxidative stress-induced diseases [136]. In humans, MUTYH
826 germline mutations have been linked to a recessive form of familial adenomatous polyposis
827 and colorectal cancer predisposition known as MUTYH-associated polyposis (MAP). One
828 notable variant, Tyr165Cys (rs34612342), causes the Tyr residue to intercalate directly into the
829 DNA duplex between 8-OHG and the nucleoside, resulting in structural changes and reduced
830 interaction capabilities. Individuals with this variant might exhibit increased risk for oxidative
831 stress-induced DNA damage due to reduced DNA glycosylase activity [136].

832 **APEX1 Gene**

833 The APEX1 gene, also referred to as the apurinic/aprimidinic endonuclease 1 gene, encodes
834 the multifunctional protein, APEX1. This protein is a key player in the BER pathway which is
835 an essential mechanism for repairing DNA damage. Specifically, APEX1 is responsible for
836 addressing DNA lesions resulting from oxidative stress. Acting as an endonuclease, it targets
837 and cleaves DNA at sites of apurinic/aprimidinic (AP) damage which is a common

838 consequence of oxidative stress. By initiating the incision of damaged DNA strands, APEX1
839 commences the repair process, enabling other enzymes to remove and replace the affected
840 nucleotides, ultimately restoring the integrity of the DNA molecule [137].

841 Various genetic alterations in the APEX1 gene have been identified, including the 468 T>G
842 (rs1760944), c.444 T>G (rs1130409), and rs3136817 polymorphisms. Among these, the
843 rs1760944 polymorphism involves a T to G substitution at position 468 within the APEX1
844 gene's promoter region. Notably, individuals with the TT genotype may experience altered
845 DNA repair efficiency under oxidative stress compared to those with GG or GT genotypes
846 [138]. Another significant polymorphism, rs1130409, represents a T>G transversion at position
847 2197 in exon 5, resulting in the substitution of aspartate with glutamate. This substitution has
848 been linked to the increased frequency of chromosomal aberrations. Functional studies suggest
849 that the variant allele G affects APEX1's endonuclease and DNA-binding activity. This may
850 result in reducing APEX1's interaction with other BER proteins and lowering its DNA repair
851 efficiency in comparison to T variants [139]. Similarly, the rs3136817 (T>C) polymorphism is
852 associated with variations in the DNA repair capacity, particularly under oxidative stress-
853 induced DNA damage. This SNP affects specific base pairs within the APEX1 gene sequence,
854 with TC and CC genotypes linked to enhanced DNA repair capacity in comparison to TT
855 genotypes [140].

856 **PARP1**

857 PARP-1 is a key gene that encodes the enzyme Poly (ADP-ribose) polymerase 1 responsible
858 for DNA repair. It plays a crucial role in BER and the repair of single-strand breaks induced
859 by ionizing radiation and oxidative damage. One of the significant SNPs investigated in
860 relation to PARP1 activity and the risk of oxidative stress-related diseases such as cataract is
861 rs1136410 (A>G). Individuals with AG and GG genotypes exhibit lower activity of the PARP
862 enzyme leading to increased susceptibility to oxidative DNA damage compared to those with
863 AA genotypes. [141].

864 **XPD**

865 The XPD gene (also known as ERCC2) encodes the helicase protein, Xeroderma Pigmentosum
866 group D. It is crucial for transcription-coupled NER, contributing to unwinding DNA and
867 excising damaged DNA fragments. Genetic variations influencing enzyme activity can impact
868 the protein's capacity to repair DNA damage caused by environmental and endogenous factors.
869 One notable polymorphism in the XPD gene is rs13181 (Lys751Gln (A/C)). Individuals with
870 the CC and CA genotypes may have impaired NER function affecting the recognition and
871 repair of DNA damage. Studies show that individuals with CC and CA genotypes exhibit
872 decreased DNA repair capacity, whereas the AA variant is associated with enhanced protection
873 against oxidative DNA damage. As a result, CC and CA genotypes are at an increased risk for
874 oxidative DNA damage [142].

875 **XRCC1**

876 The XRCC1 gene encodes for X-ray cross-complementing group 1, a DNA repair protein
877 involved in single-strand breaks (SSBs) and the BER pathway. It has been reported to be
878 responsible for the efficient repair of DNA damage caused by active oxygen, ionization, and
879 alkylating agents. Its multidomain protein structure interacts with the nicked DNA and
880 participates with at least three different enzymes to repair SSBs. These enzymes include poly-

881 ADP-ribose polymerase (PARP), DNA ligase III, and DNA polymerase β [143]. Many
882 polymorphisms have been detected in the XRCC1 gene, and three of them received most
883 attention.

884 A functional SNP rs25487 caused due to single base change from G to A results in the
885 substitution of glutamine amino acid in place of arginine. This single base change variation
886 causes complete disturbance in the functioning of XRCC1 gene resulting in its lower capability
887 to mediate BER repair. When DNA repair proteins become deficient, probably due to genetic
888 alterations, it can lead to the initiation or can further aggravate oxidative stress related disease
889 development [143]. Another notable polymorphism in XRCC1 is the rs1799782 exon 6, C>T
890 polymorphism. The T allele results in amino acid substitutions that modify protein function
891 and alters cellular ability to repair endogenous and exogenous DNA damage, leading to
892 oxidative stress-related disease susceptibility [143].

893 **XRCC3**

894 The X-ray repair cross-complementing group 3 (XRCC3) gene belongs to the RAD51 family.
895 It encodes a protein crucial for participating in homologous recombination (HR) double-strand
896 break repairs (DSBRs), essential for maintaining chromosomal stability. In HR-DSBR, when
897 a DNA double-strand break occurs, an undamaged sister chromatid or homologous
898 chromosome serves as a template for accurately repairing the break. Variations in the XRCC3
899 gene can affect its repair function. Among the notable polymorphisms within the XRCC3 gene
900 is Thr241Met (rs861539), characterized by a C to T transition leading to an amino acid
901 substitution from threonine to methionine at codon 241. This substitution may alter DNA repair
902 capacity by affecting the ability of the HR machinery to recognize and bind to the DNA
903 template, promote strand invasion, and facilitate DNA synthesis and ligation. Consequently,
904 individuals carrying the TT genotype may exhibit decreased or lost DNA repair capacity
905 compared to those with CT and CC genotypes [143]. The gist of the mechanisms by which
906 genetic polymorphisms affect DNA repair genes have been enlisted in Table 3.

907 **Protein repair genes in oxidative stress**

908 **Methionine sulfoxide reductase A**

909 The MSRA gene encodes for Methionine sulfoxide reductase A, an enzyme crucial for
910 repairing oxidative damage to proteins. It operates by reducing methionine sulfoxide (MetO),
911 the oxidized form of methionine, back to methionine, therefore restoring biological activity.
912 This repair mechanism helps counteract the harmful effects of oxidative stress on proteins,
913 preventing misfolding and dysfunction [144]. In the context of chronic obstructive pulmonary
914 disease (COPD), the protein alpha-1-antitrypsin (A1AT) plays a key role in protecting lung
915 tissue from damage by neutrophil elastase. However, oxidation of methionine residues in
916 A1AT can impair its function, leading to a deficiency in protecting the lung parenchyma.
917 Studies have shown that MSRA can partially restore the function of oxidized A1AT, indicating
918 its role in repairing oxidative damage in proteins. Research on the rs10903323 polymorphism
919 in the MSRA gene has indicated a potential link to COPD severity. The minor G allele of
920 rs10903323 is associated with higher levels of oxidized A1AT in COPD smokers, particularly
921 in severe COPD cases in comparison to A allele. This indicates that the G allele is associated
922 with altered MSRA activity which may influence the susceptibility to COPD by affecting the
923 repair efficiency of oxidatively damaged proteins, including A1AT. This underscores the

924 interplay between genetic variations and susceptibility to COPD mediated by oxidative damage
925 [144] (Table 3).

926 **Conclusion**

927 The review has explored the intricate relationship between genetic predispositions and
928 oxidative stress which could be associated with the pathogenesis of various conditions.
929 Through the assessment of single nucleotide polymorphisms (SNPs) relevant to oxidative
930 stress, we have highlighted the significant impact of genetic variations in the prooxidant genes,
931 XDH, CYBA, CYP1A1, PTGS2, NOS, MAO and the antioxidant genes, SOD, CAT, GPX,
932 GSS, GLUL, GSR, GSTM1, GSTM5, GSTP1, TXN, and HMOX1 on oxidative stress
933 susceptibility. These polymorphic variations can influence the expression and activity of the
934 encoded proteins, thereby disrupting the delicate redox balance in the body. Furthermore, our
935 exploration of DNA repair genes, including OGG1, NEIL1, NEIL2, MUTYH, APEX1,
936 PARP1, XRCC1, XPD, XRCC3, and the protein repair gene, MSRA, has underscored their
937 critical roles in maintaining genomic and proteomic integrity in the face of oxidative
938 challenges. Alterations in these genes contribute to the intricate network regulating DNA and
939 protein repair mechanisms, ultimately impacting an individual's susceptibility to oxidative
940 stress-related diseases.

941 Genetic assessment of the three integral gene categories can help in understanding variations
942 in the enzymes and pathways associated with oxidative stress. This information can provide
943 insights into the individual's innate potential to produce and combat oxidant species as well as
944 repair oxidative stress damage. Additionally, genetic assessment allows the early detection of
945 individuals at a higher risk of oxidative stress, potentially predisposing them to oxidative stress-
946 related conditions. This enables the timely implementation of mitigation strategies. The
947 integration of genetic insights into treatment measures allows the employment of personalized
948 medicine, interventional strategies that are designed to cater to one's genetic profile. While
949 understanding genetics can help in deciphering the body's innate potential to combat oxidative
950 stress, assessment of biological markers can provide the actual representation of the degree of
951 oxidative stress in the body. Quantification of the oxidative damage markers, lipid
952 peroxidation, DNA, RNA, and protein damage markers, can evaluate the extent of oxidative
953 damage caused to these biomolecules. In addition, measuring the levels of endogenous and
954 exogenous antioxidants can indicate the body's antioxidant capacity and its ability to
955 counteract oxidative stress. Therefore, genetic assessment along with routine testing for
956 oxidative damage and antioxidant markers is important in managing oxidative stress. While
957 genetics can drive the formulation of personalized interventions, routine biomarker assessment
958 can monitor the effectiveness of the interventions in reducing oxidative stress. Effective
959 assessment of oxidative stress and the implementation of personalized medicine can to
960 optimize cellular function, and reduce the risk of age-associated chronic diseases, thereby
961 promoting longevity.

962 In conclusion, this review sheds light on the current understanding of genetic determinants of
963 prooxidants, antioxidants, and repair genes, offering a comprehensive perspective on how
964 variations in these genes can modulate the risk of oxidative stress. Moving forward, further
965 research is warranted to elucidate the precise molecular mechanisms underlying these genetic
966 associations and to develop targeted interventions for mitigating the adverse effects of
967 oxidative stress on health.

968 References:

- 969 1. Di Meo, S., & Venditti, P. (2020). Evolution of the knowledge of free radicals and other
970 oxidants. *Oxidative Medicine and Cellular Longevity*, 2020.
- 971 2. Checa, J., & Aran, J. M. (2020). Reactive oxygen species: drivers of physiological and
972 pathological processes. *Journal of Inflammation research*, 1057-1073.
- 973 3. Huchzermeyer, B., Menghani, E., Khardia, P., & Shilu, A. (2022). Metabolic pathway
974 of natural antioxidants, antioxidant enzymes and ROS providence. *Antioxidants*, 11(4),
975 761.
- 976 4. Hajam, Y. A., Rani, R., Ganie, S. Y., Sheikh, T. A., Javaid, D., Qadri, S. S., ... & Reshi,
977 M. S. (2022). Oxidative stress in human pathology and aging: Molecular mechanisms
978 and perspectives. *Cells*, 11(3), 552.
- 979 5. Bhattacharyya, A., Chattopadhyay, R., Mitra, S., & Crowe, S. E. (2014). Oxidative
980 stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.
981 *Physiological reviews*, 94(2), 329-354.
- 982 6. Ramírez-Expósito, M. J., & Martínez-Martos, J. M. (2019). The delicate equilibrium
983 between oxidants and antioxidants in brain glioma. *Current neuropharmacology*, 17(4),
984 342-351.
- 985 7. Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010). Oxidative
986 stress, inflammation, and cancer: how are they linked?. *Free radical biology and*
987 *medicine*, 49(11), 1603-1616.
- 988 8. Andreadi, A., Bellia, A., Di Daniele, N., Meloni, M., Lauro, R., Della-Morte, D., &
989 Lauro, D. (2022). The molecular link between oxidative stress, insulin resistance, and
990 type 2 diabetes: A target for new therapies against cardiovascular diseases. *Current*
991 *opinion in pharmacology*, 62, 85-96.
- 992 9. Scandalios, J. G. (2005). Oxidative stress: molecular perception and transduction of
993 signals triggering antioxidant gene defenses. *Brazilian journal of medical and*
994 *biological research*, 38, 995-1014.
- 995 10. Gusti, A. M., Qusti, S. Y., Alshammari, E. M., Toraih, E. A., & Fawzy, M. S. (2021).
996 Antioxidants-Related Superoxide Dismutase (SOD), catalase (CAT), glutathione
997 peroxidase (GPX), glutathione-S-transferase (GST), and nitric oxide synthase (NOS)
998 gene variants analysis in an obese population: A preliminary case-control study.
999 *Antioxidants*, 10(4), 595.
- 1000 11. Ayala, A., Muñoz, M. F., & Argüelles, S. (2014). Lipid peroxidation: production,
1001 metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal.
1002 *Oxidative medicine and cellular longevity*, 2014.
- 1003 12. Santos, L. F. D. S. S. (2021). DNA repair SNPs as genetic modulators of individual
1004 susceptibility to differentiated thyroid cancer and response to radioiodine therapy.
- 1005 13. Oien, D. B., & Moskovitz, J. (2007). Substrates of the methionine sulfoxide reductase
1006 system and their physiological relevance. *Current Topics in Developmental Biology*,
1007 80, 93-133.
- 1008 14. Sachdev, S., Ansari, S. A., Ansari, M. I., Fujita, M., & Hasanuzzaman, M. (2021).
1009 Abiotic stress and reactive oxygen species: Generation, signaling, and defense
1010 mechanisms. *Antioxidants*, 10(2), 277.
- 1011 15. Martemucci, G., Costagliola, C., Mariano, M., D'andrea, L., Napolitano, P., &
1012 D'Alessandro, A. G. (2022). Free radical properties, source and targets, antioxidant
1013 consumption and health. *Oxygen*, 2(2), 48-78.

- 1014 16. Pham-Huy, L. A., He, H., & Pham-Huy, C. (2008). Free radicals, antioxidants in
1015 disease and health. *International journal of biomedical science: IJBS*, 4(2), 89.
- 1016 17. Chaudhary, P., Janmeda, P., Docea, A. O., Yeskaliyeva, B., Abdull Razis, A. F., Modu,
1017 B., ... & Sharifi-Rad, J. (2023). Oxidative stress, free radicals and antioxidants: potential
1018 crosstalk in the pathophysiology of human diseases. *Frontiers in chemistry*, 11,
1019 1158198.
- 1020 18. He, L., He, T., Farrar, S., Ji, L., Liu, T., & Ma, X. (2017). Antioxidants maintain cellular
1021 redox homeostasis by elimination of reactive oxygen species. *Cellular Physiology and*
1022 *Biochemistry*, 44(2), 532-553.
- 1023 19. Santos-Sánchez, N. F., Salas-Coronado, R., Villanueva-Cañongo, C., & Hernández-
1024 Carlos, B. (2019). Antioxidant compounds and their antioxidant mechanism.
1025 *Antioxidants*, 10, 1-29.
- 1026 20. Kumar, R., Joshi, G., Kler, H., Kalra, S., Kaur, M., & Arya, R. (2018). Toward an
1027 understanding of structural insights of xanthine and aldehyde oxidases: an overview of
1028 their inhibitors and role in various diseases. *Medicinal Research Reviews*, 38(4), 1073-
1029 1125.
- 1030 21. Harrison, R. (2002). Structure and function of xanthine oxidoreductase: where are we
1031 now?. *Free Radical Biology and Medicine*, 33(6), 774-797.
- 1032 22. Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, Lapatto
1033 R. Increased kidney xanthine oxidoreductase activity in salt-induced experimental
1034 hypertension. *Hypertension* 1998; 32:902–906
- 1035 23. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, et al. Xanthine
1036 oxidase activity associated with arterial blood pressure in spontaneously hypertensive
1037 rats. *Proc Natl Acad Sci U S A* 1998; 95:4754–4759.
- 1038 24. Alderman, M. H., Cohen, H., Madhavan, S., & Kivlighn, S. (1999). Serum uric acid
1039 and cardiovascular events in successfully treated hypertensive patients. *Hypertension*,
1040 34(1), 144-150.
- 1041 25. Chaves, F. J., Corella, D., Blesa, S., Mansego, M. L., Marín, P., Portoles, O., ... &
1042 Redon, J. (2007). Xanthine oxidoreductase polymorphisms: influence in blood pressure
1043 and oxidative stress levels. *Pharmacogenetics and genomics*, 17(8), 589-596.
- 1044 26. Aviello, G., & Knaus, U. G. (2018). NADPH oxidases and ROS signaling in the
1045 gastrointestinal tract. *Mucosal immunology*, 11(4), 1011-1023.
- 1046 27. Kumar, R., Kohli, S., Ali, Z., Duhan, K., Ram, R., Gupta, M., ... & Pasha, M. A. (2015).
1047 CYBA (p22phox) variants associate with blood pressure and oxidative stress markers
1048 in hypertension: a replication study in populations of diverse altitudes. *Hypertension*
1049 *Research*, 38(7), 498-506.
- 1050 28. Ortega-Loubon, C., Martínez-Paz, P., García-Morán, E., Tamayo-Velasco, Á., López-
1051 Hernández, F. J., Jorge-Monjas, P., & Tamayo, E. (2021). Genetic susceptibility to
1052 acute kidney injury. *Journal of Clinical Medicine*, 10(14), 3039.
- 1053 29. Tupurani, M. A., Padala, C., Puranam, K., Galimudi, R. K., Kupsal, K., Shyamala, N.,
1054 ... & Hanumanth, S. R. (2018). Association of CYBA gene (-930 A/G and 242 C/T)
1055 polymorphisms with oxidative stress in breast cancer: a case-control study. *PeerJ*, 6,
1056 e5509.
- 1057 30. San José, G., Fortuno, A., Beloqui, O., Diez, J., & Zalba, G. (2008). NADPH oxidase
1058 CYBA polymorphisms, oxidative stress and cardiovascular diseases. *Clinical Science*,
1059 114(3), 173-182.

- 1060 31. Najafi, M., Alipoor, B., Shabani, M., Amirfarhangi, A., & Ghasemi, H. (2012).
1061 Association between rs4673 (C/T) and rs13306294 (A/G) haplotypes of NAD (P) H
1062 oxidase p22phox gene and severity of stenosis in coronary arteries. *Gene*, 499(1), 213-
1063 217.
- 1064 32. Kheirandish-Gozal, L., & Gozal, D. (2013). Genotype–phenotype interactions in
1065 pediatric obstructive sleep apnea. *Respiratory physiology & neurobiology*, 189(2), 338-
1066 343.
- 1067 33. Danielson, P. Á. (2002). The cytochrome P450 superfamily: biochemistry, evolution
1068 and drug metabolism in humans. *Current drug metabolism*, 3(6), 561-597.
- 1069 34. Stading, R., Chu, C., Couroucli, X., Lingappan, K., & Moorthy, B. (2020). Molecular
1070 role of cytochrome P4501A enzymes in oxidative stress. *Current opinion in toxicology*,
1071 20, 77-84.
- 1072 35. Kiyohara, C., Washio, M., Horiuchi, T., Asami, T., Ide, S., Atsumi, T., ... & Kyushu
1073 Sapporo SLE (KYSS) Study Group. (2012). Risk modification by CYP1A1 and
1074 GSTM1 polymorphisms in the association of cigarette smoking and systemic lupus
1075 erythematosus in a Japanese population. *Scandinavian journal of rheumatology*, 41(2),
1076 103-109.
- 1077 36. Peddireddy, V., Badabagni, S. P., Gundimeda, S. D., Mamidipudi, V., Penagaluru, P.
1078 R., & Mundluru, H. P. (2016). Association of CYP1A1, GSTM1 and GSTT1 gene
1079 polymorphisms with risk of non-small cell lung cancer in Andhra Pradesh region of
1080 South India. *European journal of medical research*, 21, 17.
- 1081 37. Kim, H. J., Park, J. H., Seo, Y. S., Holsen, T. M., Hopke, P. K., Sung, J., ... & Kim, J.
1082 I. (2018). CYP1A1 gene polymorphisms modify the association between PM10
1083 exposure and lung function. *Chemosphere*, 203, 353-359.
- 1084 38. Jaén, R. I., Prieto, P., Casado, M., Martín-Sanz, P., & Boscá, L. (2018). Post-
1085 translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal
1086 cancer: An update. *World journal of gastroenterology*, 24(48), 5454.
- 1087 39. Simmons, D. L., Botting, R. M., & Hla, T. (2004). Cyclooxygenase isozymes: the
1088 biology of prostaglandin synthesis and inhibition. *Pharmacological reviews*, 56(3),
1089 387-437.
- 1090 40. Kim, J. H., Lee, M. R., & Hong, Y. C. (2016). Modification of the association of
1091 bisphenol A with abnormal liver function by polymorphisms of oxidative stress-related
1092 genes. *Environmental research*, 147, 324-330.
- 1093 41. Benelli, R., Venè, R., & Ferrari, N. (2018). Prostaglandin-endoperoxide synthase 2
1094 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.
1095 *Translational Research*, 196, 42-61.
- 1096 42. Katkam, S. K., Indumathi, B., Naushad, S. M., & Kutala, V. K. (2019). Impact of
1097 genetic and epigenetic factors on the oxidative stress in cardiovascular disease.
1098 *Modulation of Oxidative Stress in Heart Disease*, 107-128.
- 1099 43. Roberts, R. A., Laskin, D. L., Smith, C. V., Robertson, F. M., Allen, E. M., Doorn, J.
1100 A., & Slikker, W. (2009). Nitrate and oxidative stress in toxicology and disease.
1101 *Toxicological sciences*, 112(1), 4-16.
- 1102 44. Gholamalizadeh, M., Majidi, N., Tajaddod, S., Abdollahi, S., Poorhosseini, S. M.,
1103 Ahmadzadeh, M., ... & Houshiar-Rad, A. (2022). Interactions of Colorectal Cancer,
1104 Dietary Fats, and Polymorphisms of Arachidonate Lipoxygenase and Cyclooxygenase
1105 Genes: A Literature Review. *Frontiers in Oncology*, 12, 865208.

- 1106 45. Rudnicka, K., Backert, S., & Chmiela, M. (2019). Genetic polymorphisms in
1107 inflammatory and other regulators in gastric cancer: risks and clinical consequences.
1108 molecular mechanisms of inflammation: induction, resolution and escape by
1109 helicobacter pylori, 53-76.
- 1110 46. Cinel, L., Polat, A., Aydin, Ö., Düşmez, D., & Eğılmez, R. (2002). Bcl-2, iNOS, p53
1111 and PCNA expression in normal, disordered proliferative, hyperplastic and malignant
1112 endometrium. *Pathology international*, 52(5-6), 384-389.
- 1113 47. Chaaben, A. B., Mariaselvam, C., Salah, S., Busson, M., Dulphy, N., Douik, H., ... &
1114 Tamouza, R. (2015). Polymorphisms in oxidative stress-related genes are associated
1115 with nasopharyngeal carcinoma susceptibility. *Immunobiology*, 220(1), 20-25.
- 1116 48. Nosarev, A. V., Smagliy, L. V., Anfinogenova, Y., Popov, S. V., & Kapilevich, L. V.
1117 (2015). Exercise and NO production: relevance and implications in the
1118 cardiopulmonary system. *Frontiers in cell and developmental biology*, 2, 73.
- 1119 49. Synowiec, E., Wigner, P., Cichon, N., Watala, C., Czarny, P., Saluk-Bijak, J., ... &
1120 Bijak, M. (2021). Single-nucleotide polymorphisms in oxidative stress-related genes
1121 and the risk of a stroke in a Polish population—A preliminary study. *Brain Sciences*,
1122 11(3), 391.
- 1123 50. Pacanowski, M. A., Zineh, I., Cooper-DeHoff, R. M., Pepine, C. J., & Johnson, J. A.
1124 (2009). Genetic and pharmacogenetic associations between NOS3 polymorphisms,
1125 blood pressure, and cardiovascular events in hypertension. *American journal of*
1126 *hypertension*, 22(7), 748-753.
- 1127 51. Kondkar, A. A., Azad, T. A., Sultan, T., Osman, E. A., Almobarak, F. A., & Al-
1128 Obeidan, S. A. (2020). Association of endothelial nitric oxide synthase (NOS3) gene
1129 polymorphisms with primary open-angle glaucoma in a Saudi cohort. *PLoS One*, 15(1),
1130 e0227417.
- 1131 52. Nath, S. D., He, X., Voruganti, V. S., Blangero, J., MacCluer, J. W., Comuzzie, A. G.,
1132 ... & Thameem, F. (2009). The 27-bp repeat polymorphism in intron 4 (27 bp-VNTR)
1133 of endothelial nitric oxide synthase (eNOS) gene is associated with albumin to
1134 53. Kaludercic, N., Mialet-Perez, J., Paolocci, N., Parini, A., & Di Lisa, F. (2014).
1135 Monoamine oxidases as sources of oxidants in the heart. *Journal of molecular and*
1136 *cellular cardiology*, 73, 34-42.
- 1137 54. Ramsay, R. R. (2016). Molecular aspects of monoamine oxidase B. *Progress in neuro-*
1138 *psychopharmacology and biological Psychiatry*, 69, 81-89.
- 1139 55. Leko, M. B., Perković, M. N., Erjavec, G. N., Klepac, N., Štrac, D. Š., Borovečki, F.,
1140 ... & Šimič, G. (2021). Association of the MAOB rs1799836 Single Nucleotide
1141 Polymorphism and APOE ε4 Allele in Alzheimer's Disease. *Current Alzheimer*
1142 *Research*, 18(7), 585-594.
- 1143 56. Angelopoulou, E., Bougea, A., Papageorgiou, S. G., & Villa, C. (2022). Psychosis in
1144 Parkinson's Disease: A Lesson from Genetics. *Genes*, 13(6), 1099.
- 1145 57. Barry, H. (2018). SUPEROXIDE DISMUTASE AND THE SUPEROXIDE THEORY
1146 OF OXYGEN TOXICITY. A CRITICAL APPRAISAL. *Copper Proteins and Copper*
1147 *Enzymes: Volume II*, 2.
- 1148 58. Ściskalska, M., Ołdakowska, M., Marek, G., & Milnerowicz, H. (2020). Changes in the
1149 activity and concentration of superoxide dismutase isoenzymes (Cu/Zn SOD, MnSOD)
1150 in the blood of healthy subjects and patients with acute pancreatitis. *Antioxidants*,
1151 9(10), 948.

- 1152 59. Aranda-Rivera, A. K., Cruz-Gregorio, A., Arancibia-Hernández, Y. L., Hernández-
1153 Cruz, E. Y., & Pedraza-Chaverri, J. (2022). RONS and oxidative stress: An overview
1154 of basic concepts. *Oxygen*, 2(4), 437-478.
- 1155 60. Saxena, P., Selvaraj, K., Khare, S. K., & Chaudhary, N. (2022). Superoxide dismutase
1156 as multipotent therapeutic antioxidant enzyme: Role in human diseases. *Biotechnology*
1157 *Letters*, 1-22.
- 1158 61. Eleutherio, E. C. A., Magalhães, R. S. S., de Araújo Brasil, A., Neto, J. R. M., & de
1159 Holanda Paranhos, L. (2021). SOD1, more than just an antioxidant. *Archives of*
1160 *Biochemistry and Biophysics*, 697, 108701.
- 1161 62. Ben Anes, A., Ben Nasr, H., Garrouche, A., Bchir, S., Dhaouefi, Z., Chabchoub, E., ...
1162 & Chahed, K. (2019). The Cu/Zn superoxide dismutase+ 35A/C (rs2234694) variant
1163 correlates with altered levels of protein carbonyls and glutathione and associates with
1164 severity of COPD in a Tunisian population. *Free Radical Research*, 53(3), 293-303.
- 1165 63. Gallegos-Arreola, M. P., Ramírez-Hernández, M. A., Figuera, L. E., Zúñiga-González,
1166 G. M., & Puebla-Pérez, A. M. (2020). The rs2234694 and 50 bp Insertion/Deletion
1167 polymorphisms of the SOD1 gene are associated with breast cancer risk in a Mexican
1168 population. *European Review for Medical & Pharmacological Sciences*, 24(15).
- 1169 64. Sedaghat, M. R., Shiri, H., Tavakkol-Afshari, J., Norouzmahani, M. E., Bahri, F.,
1170 Fooladi, S., ... & Sadeghi, J. (2024). Impact of a 50bp insertion/deletion polymorphism
1171 of the superoxide dismutase-1 on oxidative stress status and risk of keratoconus.
1172 *Experimental Eye Research*, 238, 109742.
- 1173 65. Mirsadraee, N., & Saadat, M. (2019). Association between a 50bp Ins/Del
1174 polymorphism at the promoter region of the superoxide dismutase-1 and age of onset
1175 of schizophrenia. *EXCLI journal*, 18, 204.
- 1176 66. Zelko, I. N., Mariani, T. J., & Folz, R. J. (2002). Superoxide dismutase multigene
1177 family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD
1178 (SOD3) gene structures, evolution, and expression. *Free Radical Biology and*
1179 *Medicine*, 33(3), 337-349.
- 1180 67. Flynn, J. M., & Melov, S. (2013). SOD2 in mitochondrial dysfunction and
1181 neurodegeneration. *Free Radical Biology and Medicine*, 62, 4-12.
- 1182 68. Dong, L. (2009). Development and validation of in vivo sensors of mitochondrial redox
1183 status (Doctoral dissertation, University of South Carolina).
- 1184 69. Pourvali, K., Abbasi, M., & Mottaghi, A. (2016). Role of superoxide dismutase 2 gene
1185 Ala16Val polymorphism and total antioxidant capacity in diabetes and its
1186 complications. *Avicenna journal of medical biotechnology*, 8(2), 48.
- 1187 70. Holley, A. K., Bakthavatchalu, V., Velez-Roman, J. M., & St. Clair, D. K. (2011).
1188 Manganese superoxide dismutase: guardian of the powerhouse. *International journal of*
1189 *molecular sciences*, 12(10), 7114-7162.
- 1190 71. Gao, F., Kinnula, V. L., Myllärniemi, M., & Oury, T. D. (2008). Extracellular
1191 superoxide dismutase in pulmonary fibrosis. *Antioxidants & redox signaling*, 10(2),
1192 343-354.
- 1193 72. Bezerra, F. S., Lanzetti, M., Nesi, R. T., Nagato, A. C., Silva, C. P. E., Kennedy-Feitosa,
1194 E., ... & Valenca, S. S. (2023). Oxidative Stress and Inflammation in Acute and Chronic
1195 Lung Injuries. *Antioxidants*, 12(3), 548.

- 1196 73. Griess, B., Tom, E., Domann, F., & Teoh-Fitzgerald, M. (2017). Extracellular
1197 superoxide dismutase and its role in cancer. *Free Radical Biology and Medicine*, 112,
1198 464-479.
- 1199 74. Gongora, M. C., Lob, H. E., Landmesser, U., Guzik, T. J., Martin, W. D., Ozumi, K.,
1200 ... & Harrison, D. G. (2008). Loss of extracellular superoxide dismutase leads to acute
1201 lung damage in the presence of ambient air: a potential mechanism underlying adult
1202 respiratory distress syndrome. *The American journal of pathology*, 173(4), 915-926.
- 1203 75. Sørheim, I. C., DeMeo, D. L., Washko, G., Litonjua, A., Sparrow, D., Bowler, R., ... &
1204 Hersh, C. P. (2010). Polymorphisms in the superoxide dismutase-3 gene are associated
1205 with emphysema in COPD. *COPD: Journal of Chronic Obstructive Pulmonary*
1206 *Disease*, 7(4), 262-268.
- 1207 76. Ighodaro, O. M., & Akinloye, O. A. (2018). First line defence antioxidants-superoxide
1208 dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their
1209 fundamental role in the entire antioxidant defence grid. *Alexandria journal of medicine*,
1210 54(4), 287-293.
- 1211 77. Kodytková, J., Vávrová, L., Kocík, M., & Zak, A. (2014). Human catalase, its
1212 polymorphisms, regulation and changes of its activity in different diseases. *Folia*
1213 *biologica*, 60(4), 153.
- 1214 78. McCullough, L. E., Santella, R. M., Cleveland, R. J., Bradshaw, P. T., Millikan, R. C.,
1215 North, K. E., ... & Gammon, M. D. (2012). Polymorphisms in oxidative stress genes,
1216 physical activity, and breast cancer risk. *Cancer Causes & Control*, 23, 1949-1958.
- 1217 79. Wu, J., Jiang, Z., Huang, X., Luo, Z., & Peng, H. (2023). Association of polymorphisms
1218 in the catalase gene with the susceptibility to noise-induced hearing loss: A meta-
1219 analysis. *American Journal of Otolaryngology*, 44(2), 103699.
- 1220 80. Hebert-Schuster, M., Fabre, E. E., & Nivet-Antoine, V. (2012). Catalase
1221 polymorphisms and metabolic diseases. *Current Opinion in Clinical Nutrition &*
1222 *Metabolic Care*, 15(4), 397-402.
- 1223 81. Sirivarasai, J., Kaojarern, S., Chanprasertyothin, S., Panpunuan, P., Petchpoung, K.,
1224 Tatsaneeyapant, A., ... & Sritara, P. (2015). Environmental lead exposure, catalase
1225 gene, and markers of antioxidant and oxidative stress relation to hypertension: an
1226 analysis based on the EGAT study. *BioMed research international*, 2015.
- 1227 82. Kim, S. K., Kang, S. W., Chung, J. H., Park, H. J., Cho, K. B., & Park, M. S. (2015).
1228 Genetic polymorphisms of glutathione-related enzymes (GSTM1, GSTT1, and GSTP1)
1229 and schizophrenia risk: a meta-analysis. *International Journal of Molecular Sciences*,
1230 16(8), 19602-19611.
- 1231 83. Shaparov, M. G., Gudkov, S. V., Lankin, V. Z., & Novoselov, V. I. (2021). Role of
1232 glutathione peroxidases and peroxiredoxins in free radical-induced pathologies.
1233 *Biochemistry (Moscow)*, 86, 1418-1433.
- 1234 84. Flohé, L., & Brigelius-Flohé, R. (2011). Selenoproteins of the glutathione peroxidase
1235 family. In *Selenium: Its Molecular Biology and Role in Human Health* (pp. 167-180).
1236 New York, NY: Springer New York.
- 1237 85. Toppo, S., Vanin, S., Bosello, V., & Tosatto, S. C. (2008). Evolutionary and structural
1238 insights into the multifaceted glutathione peroxidase (Gpx) superfamily. *Antioxidants*
1239 *& redox signaling*, 10(9), 1501-1514.
- 1240 86. Zhao, Y., Wang, H., Zhou, J., & Shao, Q. (2022). Glutathione peroxidase GPX1 and its
1241 dichotomous roles in cancer. *Cancers*, 14(10), 2560.

- 1242 87. Mohammedi, K., Patente, T. A., Bellili-Muñoz, N., Driss, F., Le Nagard, H., Fumeron,
1243 F., ... & Velho, G. (2016). Glutathione peroxidase-1 gene (GPX1) variants, oxidative
1244 stress and risk of kidney complications in people with type 1 diabetes. *Metabolism*,
1245 65(2), 12-19.
- 1246 88. Lubos, E., Loscalzo, J., & Handy, D. E. (2011). Glutathione peroxidase-1 in health and
1247 disease: from molecular mechanisms to therapeutic opportunities.
- 1248 89. Jerotić, Đ. (2021). Association of NRF2, SOD2 and GPX1 gene polymorphisms with
1249 markers of oxidative stress and prognosis in patients with end stage renal disease.
1250 Универзитет у Београду.
- 1251 90. Zhang, F., Li, X., & Wei, Y. (2023). Selenium and Selenoproteins in Health.
1252 *Biomolecules*, 13(5), 799.
- 1253 91. Chang, C., Worley, B. L., Phaëton, R., & Hempel, N. (2020). Extracellular glutathione
1254 peroxidase GPx3 and its role in cancer. *Cancers*, 12(8), 2197.
- 1255 92. Chien, C. Y., Huang, T. Y., Tai, S. Y., Chang, N. C., Wang, H. M., Wang, L. F., & Ho,
1256 K. Y. (2017). Glutathione peroxidase 3 gene polymorphisms and the risk of sudden
1257 sensorineural hearing loss. *The Kaohsiung Journal of Medical Sciences*, 33(7), 359-
1258 364.
- 1259 93. Voetsch, B., Jin, R. C., Bierl, C., Deus-Silva, L., Camargo, E. C., Annichino-Bizacchi,
1260 J. M., ... & Loscalzo, J. (2008). Role of promoter polymorphisms in the plasma
1261 glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis.
1262 *Stroke*, 39(2), 303-307.
- 1263 94. Weaver, K., & Skouta, R. (2022). The Selenoprotein Glutathione Peroxidase 4: From
1264 Molecular Mechanisms to Novel Therapeutic Opportunities. *Biomedicines* 2022, 10,
1265 891.
- 1266 95. Barbosa, P., Abo El-Magd, N. F., Hesketh, J., & Bermano, G. (2022). The Role of
1267 rs713041 Glutathione Peroxidase 4 (GPX4) Single Nucleotide Polymorphism on
1268 Disease Susceptibility in Humans: A Systematic Review and Meta-Analysis.
1269 *International journal of molecular sciences*, 23(24), 15762.
- 1270 96. Crawford, A., Fassett, R. G., Geraghty, D. P., Kunde, D. A., Ball, M. J., Robertson, I.
1271 K., & Coombes, J. S. (2012). Relationships between single nucleotide polymorphisms
1272 of antioxidant enzymes and disease. *Gene*, 501(2), 89-103.
- 1273 97. Deponte, M. (2022). Glutathione and glutathione-dependent enzymes. In *Redox
1274 Chemistry and Biology of Thiols* (pp. 241-275). Academic Press.
- 1275 98. Lu, S. C. (2013). Glutathione synthesis. *Biochimica et Biophysica Acta (BBA)-General
1276 Subjects*, 1830(5), 3143-3153.
- 1277 99. Sarikaya, E., & Doğan, S. (2020). Glutathione peroxidase in health and diseases.
1278 *Glutathione system and oxidative stress in health and disease*, 49.
- 1279 100. Nissar, S., Sameer, A. S., Rasool, R., Chowdri, N. A., & Rashid, F. J. J. C. M.
1280 (2017). Glutathione S transferases: biochemistry, polymorphism and role in colorectal
1281 carcinogenesis. *J. Carcinog. Mutagen*, 8(2), 287.
- 1282 101. Vašková, J., Kočan, L., Vaško, L., & Perjési, P. (2023). Glutathione-Related
1283 Enzymes and Proteins: A Review. *Molecules*, 28(3), 1447.
- 1284 102. Tretter, V., Hochreiter, B., Zach, M. L., Krenn, K., & Klein, K. U. (2021).
1285 Understanding cellular redox homeostasis: A challenge for precision medicine.
1286 *International Journal of Molecular Sciences*, 23(1), 106.

- 1287 103. Dickinson, D. A., & Forman, H. J. (2002). Cellular glutathione and thiols
1288 metabolism. *Biochemical pharmacology*, 64(5-6), 1019-1026.
- 1289 104. Kalamkar, S. D., Thorve, A. M., Gajjar, V., Divate, U., Karandikar-Iyer, S.,
1290 Goel, P., ... & Ghaskadbi, S. (2023). Single nucleotide polymorphism in glutathione
1291 synthetase gene in Indian population with type 2 diabetes. *Chronicle of Diabetes*
1292 *Research and Practice*, 2(2), 67-72.
- 1293 105. Bentley, A. R., Emrani, P., & Cassano, P. A. (2008). Genetic variation and gene
1294 expression in antioxidant-related enzymes and risk of chronic obstructive pulmonary
1295 disease: a systematic review. *Thorax*.
- 1296 106. Halama, A., & Suhre, K. (2022). Advancing cancer treatment by targeting
1297 glutamine metabolism—a roadmap. *Cancers*, 14(3), 553.
- 1298 107. Morieri, M. L., & Doria, A. (2023). Genetics of Coronary Artery Disease in
1299 Diabetes Mellitus. In *Diabetes and Cardiovascular Disease* (pp. 129-157). Cham:
1300 Springer International Publishing.
- 1301 108. Vyas, B., Bhowmik, R., Akhter, M., & Ahmad, F. J. (2022). Identification,
1302 analysis of deleterious SNPs of the human GSR gene and their effects on the structure
1303 and functions of associated proteins and other diseases. *Scientific Reports*, 12(1), 5474.
- 1304 109. Hayes, J. D., & McLellan, L. I. (1999). Glutathione and glutathione-dependent
1305 enzymes represent a co-ordinately regulated defence against oxidative stress. *Free*
1306 *radical research*, 31(4), 273-300.
- 1307 110. Fujikawa, Y., Terakado, K., Nezu, S., Noritsugu, K., Maemoto, Y., Ito, A., &
1308 Inoue, H. (2023). Improving reactivity of naphthalimide-based GST probe by imparting
1309 TPP cation: Development and application for live cell imaging. *Bioorganic &*
1310 *Medicinal Chemistry Letters*, 80, 129109.
- 1311 111. Grussy, K., Łaska, M., Moczurad, W., Król-Kulikowska, M., & Ścisłalska, M.
1312 (2023). The importance of polymorphisms in the genes encoding glutathione S-
1313 transferase isoenzymes in development of selected cancers and cardiovascular diseases.
1314 *Molecular Biology Reports*, 50(11), 9649-9661.
- 1315 112. Mortazavi, Y., Rahimi, R., Azimi, F., Rostami, S., Moghimi, M., Faghihzadeh,
1316 S., & Mazloomzadeh, S. (2020). Role of Glutathione S-transferase (GSTM1, GSTT1)
1317 and CYP1A1 (cytochrome p450) Gene polymorphisms in susceptibility to acute
1318 myeloid leukemia. *Middle East Journal of Cancer*, 11(1), 12-20.
- 1319 113. Dai, X., Bui, D. S., & Lodge, C. (2021). Glutathione S-transferase gene
1320 associations and gene-environment interactions for asthma. *Current Allergy and*
1321 *Asthma Reports*, 21(5), 31.
- 1322 114. Butrym, A., Łacina, P., Bogunia-Kubik, K., & Mazur, G. (2021). ABCC3 and
1323 GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia
1324 patients. *Current Problems in Cancer*, 45(5), 100729.
- 1325 115. Santric, V., Djokic, M., Suvakov, S., Pljesa-Ercegovac, M., Nikitovic, M.,
1326 Radic, T., ... & Savic-Radojevic, A. (2020). GSTP1 rs1138272 polymorphism affects
1327 prostate cancer risk. *Medicina*, 56(3), 128
- 1328 116. Lee, S., Kim, S. M., & Lee, R. T. (2013). Thioredoxin and thioredoxin target
1329 proteins: from molecular mechanisms to functional significance. *Antioxidants & redox*
1330 *signaling*, 18(10), 1165-1207.
- 1331 117. Hanschmann, E. M., Godoy, J. R., Berndt, C., Hudemann, C., & Lillig, C. H.
1332 (2013). Thioredoxins, glutaredoxins, and peroxiredoxins—molecular mechanisms and

- 1333 health significance: from cofactors to antioxidants to redox signaling. *Antioxidants &*
1334 *redox signaling*, 19(13), 1539-1605.
- 1335 118. Wen, S., Lu, W., Zhu, H., Yang, W., Shaw, G. M., Lammer, E. J., ... & Finnell,
1336 R. H. (2009). Genetic polymorphisms in the thioredoxin 2 (TXN2) gene and risk for
1337 spina bifida. *American Journal of Medical Genetics Part A*, 149(2), 155-160.
- 1338 119. Domingues, A., Jolibois, J., Marquet de Rougé, P., & Nivet-Antoine, V. (2021).
1339 The emerging role of TXNIP in ischemic and cardiovascular diseases; a novel marker
1340 and therapeutic target. *International Journal of Molecular Sciences*, 22(4), 1693.
- 1341 120. Ramus, S. M., Cilensek, I., Petrovic, M. G., Soucek, M., Kruzliak, P., &
1342 Petrovic, D. (2016). Single nucleotide polymorphisms in the Trx2/TXNIP and TrxR2
1343 genes of the mitochondrial thioredoxin antioxidant system and the risk of diabetic
1344 retinopathy in patients with Type 2 diabetes mellitus. *Journal of Diabetes and its*
1345 *Complications*, 30(2), 192-198.
- 1346 121. Chiang, S. K., Chen, S. E., & Chang, L. C. (2021). The role of HO-1 and its
1347 crosstalk with oxidative stress in cancer cell survival. *Cells*, 10(9), 2401.
- 1348 122. Ryter, S. W. (2022). Heme oxygenase-1: an anti-inflammatory effector in
1349 cardiovascular, lung, and related metabolic disorders. *Antioxidants*, 11(3), 555.
- 1350 123. Pandey, H., Singh, K., Ranjan, R., Dass, J., Tyagi, S., Seth, T., ... & Mahapatra,
1351 M. (2023). Prevalence and Impact of HMOX1 Polymorphism (rs2071746: A> T) in
1352 Indian Sickle Cell Disease Patients. *Journal of Laboratory Physicians*.
- 1353 124. Gibson, B. W. (2005). The human mitochondrial proteome: oxidative stress,
1354 protein modifications and oxidative phosphorylation. *The international journal of*
1355 *biochemistry & cell biology*, 37(5), 927-934.
- 1356 125. Kołodziej, U., Maciejczyk, M., & Zalewska, A. (2018). Oxidative stress–repair
1357 systems of oxidatively damaged biomolecules. *Progress in Health Sciences*, 8, 141-150.
- 1358 126. Charlier, C. F. (2018). Deciphering the Crosstalk: Characterisation of the
1359 Regulation of the ER Stress Response by the DNA Repair Enzyme AAG. University
1360 of Surrey (United Kingdom).
- 1361 127. Daimon, M., Oizumi, T., Toriyama, S., Karasawa, S., Jimbu, Y., Wada, K., ...
1362 & Kato, T. (2009). Association of the Ser326Cys polymorphism in the OGG1 gene
1363 with type 2 DM. *Biochemical and biophysical research communications*, 386(1), 26-
1364 29.
- 1365 128. Okasaka, T., Matsuo, K., Suzuki, T., Ito, H., Hosono, S., Kawase, T., ... &
1366 Tajima, K. (2009). hOGG1 Ser326Cys polymorphism and risk of lung cancer by
1367 histological type. *Journal of human genetics*, 54(12), 739-745.
- 1368 129. Berger, F., Vaslin, L., Belin, L., Asselain, B., Forlani, S., Humbert, S., ... &
1369 Hall, J. (2013). The impact of single-nucleotide polymorphisms (SNPs) in OGG1 and
1370 XPC on the age at onset of Huntington disease. *Mutation Research/Genetic Toxicology*
1371 *and Environmental Mutagenesis*, 755(2), 115-119.
- 1372 130. Gangwar, R., Ahirwar, D., Mandhani, A., & Mittal, R. D. (2009). Do DNA
1373 repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder
1374 cancer in the North Indian population?. *Mutation Research/Genetic Toxicology and*
1375 *Environmental Mutagenesis*, 680(1-2), 56-63.
- 1376 131. Simonelli, V., Mazzei, F., D'Errico, M., & Dogliotti, E. (2012). Gene
1377 susceptibility to oxidative damage: from single nucleotide polymorphisms to function.

- 1378 Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 731(1-
1379 2), 1-13.
- 1380 132. Albelazi, M. S., Martin, P. R., Mohammed, S., Mutti, L., Parsons, J. L., & Elder,
1381 R. H. (2019). The biochemical role of the human NEIL1 and NEIL3 DNA glycosylases
1382 on model DNA replication forks. *Genes*, 10(4), 315.
- 1383 133. Wilson III, D. M., Kim, D., Berquist, B. R., & Sigurdson, A. J. (2011). Variation
1384 in base excision repair capacity. *Mutation Research/Fundamental and Molecular*
1385 *Mechanisms of Mutagenesis*, 711(1-2), 100-112.
- 1386 134. Kinslow, C. J. (2008). Genetic determinants of NEIL2 transcription (Doctoral
1387 dissertation).
- 1388 135. Nakamura, T., Okabe, K., Hirayama, S., Chirifu, M., Ikemizu, S., Morioka, H.,
1389 ... & Yamagata, Y. (2021). Structure of the mammalian adenine DNA glycosylase
1390 MUTYH: insights into the base excision repair pathway and cancer. *Nucleic acids*
1391 *research*, 49(12), 7154-7163.
- 1392 136. Curia, M. C., Catalano, T., & Aceto, G. M. (2020). MUTYH: Not just polyposis.
1393 *World Journal of Clinical Oncology*, 11(7), 428.
- 1394 137. Lu, Z., Li, S., Ning, S., Yao, M., Zhou, X., Wu, Y., ... & Xie, Y. (2018).
1395 Association of the rs1760944 polymorphism in the APEX1 base excision repair gene
1396 with risk of nasopharyngeal carcinoma in a population from an endemic area in South
1397 China. *Journal of clinical laboratory analysis*, 32(2), e22238.
- 1398 138. AlMutairi, F., Ali Khan Pathan, A., Alanazi, M., Shalaby, M., Alabdulkarim,
1399 H. A., Alamri, A., ... & Reddy Parine, N. (2015). Association of DNA repair gene APE1
1400 Asp148Glu polymorphism with breast cancer risk. *Disease Markers*, 2015
- 1401 139. Wang, T., Wang, H., Yang, S., Guo, H., Zhang, B., Guo, H., ... & Su, H. (2018).
1402 Association of APEX1 and OGG1 gene polymorphisms with breast cancer risk among
1403 Han women in the Gansu Province of China. *BMC Medical Genetics*, 19, 1-9.
- 1404 140. Kaur, K., & Kaur, R. (2018). Absence of APE1 (Asp148Glu) gene
1405 polymorphism in North-West Indian population: A comparison with world population.
1406 *Meta gene*, 16, 208-212.
- 1407 141. Cui, N. H., Qiao, C., Chang, X. K., & Wei, L. (2017). Associations of PARP-1
1408 variant rs1136410 with PARP activities, oxidative DNA damage, and the risk of age-
1409 related cataract in a Chinese Han population: A two-stage case-control analysis. *Gene*,
1410 600, 70-76.
- 1411 142. Wlodarczyk, M., & Nowicka, G. (2012). XPD gene rs13181 polymorphism and
1412 DNA damage in human lymphocytes. *Biochemical genetics*, 50, 860-870.
- 1413 143. Yan, L., Li, Q., Li, X., Ji, H., & Zhang, L. (2016). Association studies between
1414 XRCC1, XRCC2, XRCC3 polymorphisms and differentiated thyroid carcinoma.
1415 *Cellular Physiology and Biochemistry*, 38(3), 1075-1084
- 1416 144. Milovanovic, V., Topic, A., Milinkovic, N., Lazic, Z., Ivosevic, A., Radojkovic,
1417 D., & Rankov, A. D. (2021). Association of the methionine sulfoxide reductase A
1418 rs10903323 gene polymorphism with functional activity and oxidative modification of
1419 alpha-1-antitrypsin in COPD patients. *Pulmonology*.
- 1420
- 1421
- 1422

1423
1424
1425

TABLES

Table 1

Prooxidant enzyme	Gene Name	rsID	Function of Mutation	References
Xanthine Oxidase	XDH	565+64CT, -337GA	Enhanced XDH activity, shifting towards oxidase function, and disrupting redox balance	[24, 25]
NADPH oxidase	CYBA	rs9932581, rs8854, rs4673	Increased CYBA promoter activity leading to enhanced NADPH oxidase function giving rise to high O ₂ ^{•-} levels	[29-32]
Cytochrome P450 enzymes	CYP1A1	rs4646903	Increased CYP1A1 activity resulting in higher ROS production	[35,36]
Cyclooxygenase-2	PTGS2	rs20417	Altered protein binding site and increased transcriptional activity result in the elevated expression of COX-2 enzyme leading to increased ROS production	[40-43]
Nitric oxide synthase	NOS1	rs1879417	Altered NOS1 function leading to increased oxidative stress	[49]
	NOS2	rs8078340, rs2779249, rs2779248	Altered NOS2 activity leading to higher *NO production implicated in oxidative stress	[47]
	NOS3	T-786C, G894T, 27bp-VNTR	Altered NOS3 activity leading to lower *NO production implicated in oxidative stress	[47,50-52]
Monoamine oxidases	MAO-B	rs1799836	Disrupted monoamine metabolism associated with elevated MAO-B activity leading to increased ROS production	[55]

1426 **Table 1.** Mechanisms of genetic polymorphisms affecting prooxidant genes

1427 Abbreviations: O₂^{•-} - superoxide; ROS – Reactive oxygen species; *NO – Nitric oxide; NOS1 - Nitric oxide
1428 synthase – 1; NOS2 - Nitric oxide synthase – 2; NOS3 - Nitric oxide synthase – 3; MAO-B - Monoamine oxidase
1429 - B

1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441

Table 2

Antioxidant enzyme	Gene Name	rsID	Function of Mutation	References
Superoxide dismutase	SOD1	rs2234694	Reduced SOD1 enzyme activity hampers the conversion of $O_2^{\cdot-}$ to H_2O_2 and O_2 , dysregulating redox balance	[62,63]
		rs36232792	Decreased promoter activity results in lower SOD1 enzyme synthesis, impairing its ability to neutralize $O_2^{\cdot-}$ radicals	[64]
	SOD2	rs4880	Accelerated degradation of SOD2 mRNA lowers SOD2 activity, potentially leading to increased oxidative stress	[69]
	SOD3	rs1799895	Impaired SOD3 (ECSOD) binding to the ECM reduces tissue SOD3 levels, leading to decreased protection against oxidative damage	[73]
Catalase	CAT	rs1001179, rs769217	Lower catalase activity and expression affects the enzyme's ability to neutralize intracellular H_2O_2	[78, 80]
		rs769214	Increased catalase transcriptional activity resulting in improved antioxidant function	[79,81]
Glutathione Peroxidase	GPX1	rs1050450	Affected catalytic enzyme activity, substrate affinity, and structural stability which may lower GPx1's ability to combat oxidative stress	[89]
		rs3805435	Reduced GPx3 enzyme levels resulting in poor antioxidant defenses and heightened oxidative stress	[92]
		rs713041	Affected selenoprotein synthesis impacting GPx4 activity and potentially increasing susceptibility to oxidative stress	[95]
Glutathione synthetase	GSS	rs121909307	Altered GSS enzyme activity, influencing the production of GSH and consequently, affecting cellular response to oxidative stress	[104]
Glutamate ammonia ligase	GLUL	rs10911021	Decreased levels of the glutamine synthetase enzyme and GSH, resulting in the increased risk of oxidative stress	[107]
Glutathione reductase	GSR	rs8190955	Lower GR levels leading to impaired cellular redox potential caused by the affected antioxidant pool; results in increased oxidative stress levels, especially in red blood cells	[107]
Glutathione transferases	GSTM1	rs366631	Reduced GSTM1 activity affects the conjugation of GSH to toxic products leading to their poor elimination and compromising GSTM1's ROS scavenging abilities	[113]
		rs3754446	Reduced mitochondrial GSTM5 activity affects GSH's conjugation to toxic products resulting in their poor elimination, thereby compromising GSTM5's ability to quench ROS in the mitochondria	[114]
		rs1138272	Abnormal GSTP1 activity decreases cellular antioxidant capacity	[115]
Thioredoxin	TXN2	rs35045487, rs4485648	Decreased transcriptional activity leads to altered TXN2 gene expression reducing its antioxidant function	[118-120]

Heme-oxygenase	HO-1	rs2071746	Reduced gene expression raises free heme concentration, promoting stress-induced erythropoiesis and increasing Hb F levels, thereby leading to oxidative stress, especially in sickle cell anemia	[123]
----------------	------	-----------	---	-------

1443 **Table 2.** Mechanisms of genetic polymorphisms affecting antioxidant genes

1444 Abbreviations: SOD1 - Superoxide Dismutase 1; O₂^{•-} - Superoxide; H₂O₂ - Hydrogen peroxide; O₂ - Oxygen;
1445 SOD2 - Superoxide Dismutase 2; SOD3 - Superoxide Dismutase 3; ECSOD - Extracellular superoxide dismutase;
1446 ECM - Extracellular matrix; GPx1 - Glutathione peroxidase 1; GPx3 - Glutathione peroxidase 3; GPx4 -
1447 Glutathione peroxidase 4; GSS - Glutathione synthetase; GSH - Glutathione; GR - Glutathione reductase; GSTM1
1448 - Glutathione S-transferase Mu 1; ROS - Reactive oxygen species; GSTM5 - Glutathione S-transferase 5; GSTP1
1449 - Glutathione S-transferase P1; TXN2 - Thioredoxin-2; Hb F - Fetal hemoglobin

1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475

Table 3

Repair enzyme	Gene Name	rsID	Function of Mutation	References
<u>DNA repair</u>				
DNA glycosylase	OGG1	rs1052133	Impaired catalytic activity lowers enzyme activity resulting in reduced BER repair rates of 8-OHG lesions	[126-127]
		Arg154His	Affected recognition of cytosine paired with 8-OHG leading to the enzyme's inability to repair the DNA site	[131]
	NEIL1	rs5745906	Dysregulated enzyme function leads to its impaired ability in excising DNA lesions in duplex DNA	[132]
		rs5745907	Reduced enzyme activity for oxidative base damage repair results in altering protein folding and thereby affecting the enzyme's capability to interact with nucleotides that have undergone a flipping motion or structural change; leads to the accumulation of oxidized DNA lesions	[132]
	NEIL2	ss74800505, rs8191518	Disrupted binding of crucial transcriptional proteins reduces the gene's expression levels, consequently affecting DNA repair	[131,134]
	MUTYH	rs34612342	Tyrosine residue intercalates directly into the DNA duplex between 8-OHG and the nucleoside, resulting in structural changes and reduced enzyme interaction, decreasing DNA repair capabilities	[136]
Apurinic/aprimidinic endonuclease 1	APEX1	rs1760944	Altered DNA repair efficiency under oxidative stress	[138]
		rs1130409	Affected DNA-binding activity results in lowered APEX1's interaction with other BER proteins, affecting DNA repair; accompanied with increased frequency of chromosomal aberrations	[139]
		rs3136817	Alteration in the gene sequence results in enhanced DNA repair capacity	[140]
Poly (ADP-ribose) polymerase 1	PARP-1	rs1136410	Reduced enzyme activity leading to increased susceptibility to oxidative DNA damage	[141]
Xeroderma Pigmentosum group D	XPB	rs13181	Impaired NER function affects the recognition and repair of damaged DNA, thereby reducing DNA repair capacity	[142]
X-ray cross-complementing group 1	XRCC1	rs25487	Affected gene function resulting in the reduced capability to mediate BER repair	[143]

		rs1799782	Altered gene modifies protein function and affects cellular ability to repair endogenous and exogenous DNA damage	[143]
X-ray repair cross-complementing group 3	XRCC3	rs861539	Affected ability of the HR machinery to recognize and bind to the DNA template, promote strand invasion, and facilitate DNA synthesis and ligation, thereby reducing DNA repair capacity	[143]
Protein repair				
Methionine sulfoxide reductase A	MSRA	rs10903323	Altered gene activity affecting the repair efficiency of oxidatively damaged proteins	[144]

1477 **Table 3.** Mechanism of genetic polymorphisms affecting DNA and protein repair genes

1478 Abbreviations: BER - Base excision repair; 8-OHG - 8-hydroxyguanine; NER - Nucleotide excision repair; HR -
1479 homologous recombination; Prx - Peroxiredoxins


1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500

1501
1502
1503
1504

FIGURES

Figure 1

OXIDATIVE BALANCE GOVERNED BY PROOXIDANTS, ANTIOXIDANTS, & OXIDATIVE DAMAGE REPAIR GENES



1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520


Figure 1. Oxidative balance is governed by prooxidants, antioxidants, & oxidative damage repair genes. This illustration indicates the interplay between prooxidant, antioxidant, and repair genes in regulating the oxidative burden in the body. Prooxidant genes regulate processes that generate oxidant species which are beneficial at low to moderate levels. However, increased levels of these species are detrimental to the body. To scavenge reactive species the body has antioxidant genes encoding antioxidants that help in combatting oxidative stress. In addition, the repair genes in the body encode repair enzymes that help cope with oxidative damage. Therefore, the action of the three classes of genes is known to govern the oxidative balance in the body.

1521

Figure 2

1522

OVERVIEW OF CELLULAR OXIDATIVE STRESS PATHWAYS AND ANTIOXIDANT DEFENSE MECHANISMS



1523

1524

1525

Figure 2. Overview of Cellular Oxidative Stress Pathways and Antioxidant Defense Mechanisms

1526 Abbreviations

1527

1528 •NO - Nitric oxide

1529 NOS - Nitric oxide synthase

1530 O₂^{•-} - Superoxide

1531 ONOO⁻ - Peroxynitrite

1532 SOD - Superoxide dismutase

1533 H₂O₂ - Hydrogen peroxide

1534 •OH - Hydroxyl radicals

1535 Fe²⁺ - Ferrous iron

1536 CAT - Catalase

1537 GPx - Glutathione peroxidase

1538 GSH - Reduced glutathione

1539 TPx - Thioredoxin peroxidase

1540 GST - Glutathione S-transferase

1541 ROS - Reactive oxygen species

1542

1543 Figure 2. Antioxidant system in OS. NADPH oxidase, an essential component of the immune response,

1544 generates superoxide. Similarly, xanthine oxidase produces superoxide during purine metabolism. The

1545 respiratory chain, integral to cellular energy production, generates superoxide as a byproduct of

1546 electron transport. Cytochrome P450 enzymes, involved in metabolic processes, also contribute to
1547 superoxide production. Under certain conditions, nitric oxide synthase isoforms can produce
1548 superoxide, particularly when uncoupled.

1549 *NO is synthesized from the citrulline cycle by NOS enzymes. These enzymes catalyze the conversion
1550 of L-arginine to L-citrulline and NO, a process involving the oxidation of L-arginine's guanidino
1551 nitrogen. When NO reacts with $O_2^{\bullet-}$, $ONOO^-$ forms, a highly reactive nitrogen species implicated in
1552 oxidative damage to biomolecules.

1553 SOD enzymes convert superoxide radicals into H_2O_2 . These include cytosolic Cu/Zn-SOD (SOD1),
1554 mitochondrial Mn-SOD (SOD2), and extracellular SOD (SOD3). Hydrogen peroxide can produce $\bullet OH$
1555 through the Fenton reaction, a process catalyzed by transition metal ions such as Fe^{2+} . This reaction
1556 initiates chain reactions leading to oxidative damage.

1557 Catalase (CAT), located in peroxisomes, breaks down hydrogen peroxide into water and oxygen. This
1558 catalysis facilitates the conversion of hydrogen peroxide molecules into water and oxygen molecules.
1559 Moreover, the glutathione and thioredoxin systems directly reduce H_2O_2 to water. In the glutathione
1560 system, glutathione peroxidase (GPx) reduces H_2O_2 using reduced glutathione (GSH) as a cofactor.
1561 Similarly, thioredoxin peroxidase (TPx) reduces hydrogen peroxide using thioredoxin as a cofactor.
1562 Both systems protect cells from oxidative damage by detoxifying hydrogen peroxide.

1563 GSH and glutathione S-transferase (GST) are crucial in detoxifying harmful compounds. Through
1564 conjugation, GSH binds to electrophilic centers on toxic molecules, enhancing their water solubility
1565 and facilitating excretion from cells. This detoxification process aids in protecting cells from the
1566 damaging effects of xenobiotics and reactive oxygen species (ROS).

1567
1568

1569

1570

1571

1572

1573

1574

1575

1576

1577

1578

1579

1580

1581

1582

1583

1584


1585

1586

Figure 3

1587

THE NOS PATHWAY IN OXIDATIVE STRESS



1588

1589

Figure 3. The NOS Pathway in Oxidative Stress

1590 Abbreviations

1591 NOS - Nitric oxide synthase

1592 *NO - Nitric oxide

1593 O₂⁻ - Superoxide

1594 ONOO⁻ - Peroxynitrite

1595

1596 **Figure 3. The NOS Pathway in Oxidative Stress.** The figure illustrates the multifaceted pathway involving NOS in oxidative stress conditions. Under normal circumstances, NOS catalyzes the conversion of L-arginine to L-citrulline, producing *NO, a crucial signaling molecule. Additionally, dietary intake of nitrate and nitrite can contribute to *NO production through the nitrate-nitrite-NO pathway. However, in the presence of O₂⁻, generated during oxidative stress, *NO reacts to form ONOO⁻, a potent oxidant. This reaction leads to the synthesis of peroxynitrite, exacerbating oxidative stress and its detrimental effects on cellular components. The intricate interplay between NOS, O₂⁻, and NO underscores the significance of oxidative stress in various pathological conditions.

1604

1605

1606

1607

1608

1609

1610

1611

1612

1613

1614

1615

1616

1617

1618

1619

1620

1621
1622
1623
1624

Figure 4

GLUTATHIONE PATHWAY IN OXIDATIVE STRESS




Figure 4: Glutathione Pathway in Oxidative Stress

1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638

Abbreviations


- GSH – Glutathione
- GCL - Glutamate-cysteine ligase
- GSS - Glutathione synthetase
- H₂O₂ - Hydrogen peroxide
- ROS - Reactive oxygen species
- GSSG - Oxidized glutathione
- GR – Glutathione Reductase

1639 **Figure 4: Glutathione Pathway in Oxidative Stress.** This schematic illustrates the GSH pathway in
1640 oxidative stress, showcasing the synthesis of GSH and its role in the glutathione cycle. Glutamate enters
1641 the cell membrane from the extracellular space via specific transporters. Inside the cell, glutamate
1642 combines with cysteine and glycine, facilitated by the enzymes GCL and GSS, to form GSH. GSH is a
1643 critical antioxidant involved in cellular defense against oxidative stress. In the glutathione cycle, GSH
1644 reacts with ROS such as H₂O₂, catalyzed by the enzyme glutathione peroxidase GPx, to form GSSG
1645 and water. GSSG is then converted back to GSH through the action of GR, utilizing NADPH as a
1646 cofactor. This regeneration of GSH enables its continued function in scavenging ROS and maintaining
1647 redox balance within the cell. Overall, the glutathione pathway plays a crucial role in mitigating
1648 oxidative stress by synthesizing GSH, which acts as a potent antioxidant, and by recycling GSSG back
1649 to GSH, thus efficiently neutralizing harmful ROS like H₂O₂ to harmless water.
1650

1651
1652
1653
1654

Figure 5

THIOREDOXIN PATHWAY IN OXIDATIVE STRESS REGULATION



1655
1656

Figure 5: Thioredoxin Pathway in Oxidative Stress Regulation.

1657 Abbreviations

1658 Trx – Thioredoxin
1659 ROS - Reactive oxygen species
1660 Trx-S₂ - Oxidized state
1661 Trx-SH - Reduced form
1662 Prx Ox - Oxidized peroxiredoxins
1663 Prx Red – Reduced peroxiredoxins
1664 H₂O₂ - Hydrogen peroxide
1665 H₂O - Water
1666

1667 **Figure 5: Thioredoxin Pathway in Oxidative Stress Regulation.** The diagram illustrates the
1668 Trx pathway, a crucial cellular defense mechanism against oxidative stress. In response to
1669 elevated ROS, Trx undergoes reduction by NADPH-dependent thioredoxin reductase,
1670 transforming from its Trx-S₂ to its reduced form Trx-SH. The reduced Trx-SH, in turn,
1671 functions as a potent electron donor for the reduction of Prx Ox to Prx Red, essential
1672 peroxidases involved in ROS detoxification. Concurrently, Trx activates various redox-
1673 sensitive proteins by reducing their disulfide bonds, restoring their functional state. Notably,
1674 this pathway plays a pivotal role in maintaining cellular homeostasis by facilitating the
1675 conversion of H₂O₂ to H₂O, thereby mitigating oxidative damage and preserving cellular
1676 integrity.